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ABSTRACT 
Methadone is a synthetic, long-acting opioid prescribed as an analgesic for chronic pain. It has a 
single chiral center forming two enantiomers, (R)-methadone and (S)-methadone, each having 
specific pharmacological actions. Concentrations of (R)- and (S)-methadone above therapeutic 
levels have the ability to cause serious, life-threatening, and fatal side effects. Cardiotoxicity is 
caused by elevated (S)-methadone levels by prolonging the QT interval of the heart’s electrical 
cycle. In 2014, methadone accounted for only 1% of all opioids prescribed for pain, but was 
responsible for 3,400 of the 14,838 individuals (~23%) who died in the United States from 
overdoses due to prescription opioids. West Virginia (WV) and Kentucky (KY) continue to have 
significant increases in overdose death rates involving prescription opioids. These overdoses 
could be due in part to the pharmacogenetics of an individual, encompassing the ability to 
influence the pharmacokinetic and pharmacodynamic properties of methadone, contributing to 
toxicity. The principle determinant of the large interindividual variability of methadone 
pharmacokinetics is metabolism, causing a discordance in the relationship between dose, plasma 
concentrations, and side effects. Single nucleotide polymorphisms (SNPs) within the genes of 
drug metabolizing enzymes, cytochrome P450 (CYP), may be important contributing factors in 
altering CYP activity, methadone metabolism and pharmacodynamics. (S)-Methadone is 
stereoselectively metabolized in the liver by CYP2B6. The purpose of this study was to 
determine if one or more SNPs located within the CYP2B6 gene contributes to a poor 
metabolizer phenotype for unexpected methadone deaths. A study cohort was obtained from the 
WV and KY Offices of the Chief Medical Examiner consisting of 125 Caucasians who suffered 
methadone-only fatal overdoses. Genotypic frequency of three intronic SNPs (rs2279344, 
rs4803419, and rs8192719) and five exonic SNPs (rs3211371, rs3745274, rs8192709, 
xiv 
rs12721655, and rs35979566) were investigated. The differences between the observed 
genotypic frequencies were compared to the regional control group of 255 deceased Caucasian 
individuals. The frequencies of the exonic SNP rs3745274 and intronic SNP rs8192719 were 
enhanced in the methadone-only group. Higher blood methadone concentrations were observed 
in individuals who were genotyped homozygous for SNP rs3211371. The five exonic SNPs 
genotyped, and two others (rs2279343 and rs35773040), were individually expressed in COS-1 
cells. The effect of these SNPs on the catalytic activity of the CYP2B6 enzyme was assessed by 
evaluating the luminescence generated from the metabolism of luminogenic luciferin-2B6 
substrate. Additionally, inhibition studies were also conducted using clopidogrel to determine 
that the activity observed was from the CYP2B6 enzyme. Methadone was used to evaluate 
competitive inhibition with luciferin-2B6 substrate at the active site. The effect on CYP2B6 
activity by introducing individual SNP variants resulted in the following decreasing order: 
rs2279343 > rs3745274 > wild type (CYP2B6*1), rs3211371 > rs8192709 > rs35773040, 
rs35979566. Relative to the wild type CYP2B6, SNPs rs8192709, rs35773040, and rs35979566 
yielded 57%, 81%, and 94% decreased activity, respectively. Methadone inhibited the activity of 
the CYP2B6 enzyme by displacing the luciferin-2B6 substrate. Therefore, our investigations 
suggest that the differences in catalytic activity by CYP2B6 allelic variants rs8192709, 
rs35773040, and rs35979566 result in poor metabolizing phenotypes which may be contributing 
factors in decreased metabolism of (S)-methadone. Because CYP2B6 only plays a partial role in 
the metabolism of (S)-methadone, additional knowledge on the combination of SNPs on 
CYP2B6, together with SNPs on other methadone metabolizing CYP genes, can improve the 
proper therapeutic dosing for methadone, patient outcome, and the development of 
individualized medicine. 
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CHAPTER 1 
EFFECTS OF CYTOCHROME P450 SINGLE NUCLEOTIDE POLYMORPHISMS ON 
METHADONE METABOLISM AND PHARMACODYNAMICS 
 
The information in this chapter has been published in Biochemical Pharmacology. 
Ahmad, T., Valentovic, M. A., & Rankin, G. O. (2018). Effects of cytochrome P450 single 
nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochemical 
Pharmacology, 153, 196-204. doi:10.1016/j.bcp.2018.02.020 
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Abstract 
Methadone is a synthetic, long-acting opioid with a single chiral center forming two 
enantiomers, (R)-methadone and (S)-methadone, each having specific pharmacological actions. 
Concentrations of (R)- and (S)-methadone above therapeutic levels have the ability to cause 
serious, life-threatening, and fatal side effects. This toxicity can be due in part to the 
pharmacogenetics of an individual, which influences the pharmacokinetic and pharmacodynamic 
properties of the drug. Methadone is primarily metabolized in the liver by cytochrome P450 
(CYP) enzymes, predominately by CYP2B6, followed by CYP3A4, 2C19, 2D6, and to a lesser 
extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2. SNPs located within CYPs have the potential 
to play an important role in altering methadone metabolism and pharmacodynamics. Several 
SNPs in the CYP2B6, 3A4, 2C19, 2D6, and 3A5 genes result in increases in methadone plasma 
concentrations, decreased N-demethylation, and decreased methadone clearance. In particular, 
carriers of CYP2B6*6/*6 may have a greater risk for detrimental adverse effects, as methadone 
metabolism and clearance are diminished in these individuals. CYP2B6*4, on the other hand, has 
been observed to decrease plasma concentrations of methadone due to increased methadone 
clearance. The involvement, contribution, and understanding the role of SNPs in CYP2B6, and 
other CYP genes, in methadone metabolism can improve the therapeutic uses of methadone in 
patient outcome and the development of personalized medicine.  
1.1 Methadone Pharmacology 
Shortly after methadone was introduced in the United States, the Food and Drug 
Administration (FDA) approved its use as an analgesic and antitussive agent (Institute of 
Medicine, 1995). During the 1960s, evidence for the usefulness of methadone in the treatment of 
and maintenance therapy for narcotic addiction was growing (Dole & Nyswander, 1965; Joseph, 
3 
Stancliff, & Langrod, 2000). A decade later, the FDA expanded the approval for physicians and 
hospital pharmacies to dispense methadone for treating opiate addiction in treatment programs 
only (Institute of Medicine, 1995). Enrollment in a methadone maintenance treatment (MMT) 
program also has the potential to be a public health strategy for decreasing the transmission of 
infectious diseases (e.g. HIV/AIDS, hepatitis C, or other blood-borne pathogens) by reducing the 
number of opioid users reusing contaminated needles (Drucker, Lurie, Wodakt, & Alcabes, 
1998; Joseph et al., 2000; Somogyi, Barratt, Ali, & Coller, 2014).  
Methadone is a synthetic, long-acting opioid with a single chiral center that forms two 
enantiomers, R-(-)-methadone (levo-methadone) and S-(+)-methadone (dextro-methadone) 
(Anderson & Kearney, 2000; Lisberg & Scheinmann, 2013). Both enantiomers have specific 
pharmacodynamic properties and pharmacological actions. (R)-Methadone is a µ-opioid receptor 
(MOR) agonist that mimics the body’s natural endogenous opioids, endorphins and enkephalins. 
Binding of (R)-methadone to the MOR mediates therapeutic effects with the release of other 
neurotransmitters, including acetylcholine, dopamine, norepinephrine, and substance P 
(Anderson & Kearney, 2000). The effects propagated by this interaction yields reduction and 
elimination of drug cravings and withdrawal signs and symptoms of narcotics, analgesia, 
sedation, nausea, vomiting, constipation, miosis, antitussive effects, hypotension, mild 
bradycardia, and tolerance and dependence (Langrod, Lowinson, & Ruiz, 1981; Reisine, Law, 
Blake, & Tallent, 1996; Li, Kantelip, Gerritsen-van Schieveen, & Davani, 2008; Mallinckrodt 
Pharmaceuticals, Inc., 2016).  
In the United States, methadone is clinically available only as a racemic formulation 
comprised of both (R)- and (S)-methadone enantiomers (Gaertner, Voltz, & Ostgathe, 2008; 
Kapur, Hutson, Chibber, Luk, & Selby, 2011; McCance-Katz, 2011). Methadone is currently 
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used as: (1) an approved opioid substitution therapeutic agent to suppress opioid-abstinence 
syndrome in opiate abuse and addiction (Stotts, Dodrill, & Kosten, 2009; Bart, 2012; Kreek et 
al., 2012; Peles, Linzy, Kreek, & Adelson, 2013; McDonough, 2013); (2) a second-line opioid in 
alleviating cancer pain and chronic non-malignant pain, such as back, joint, or neuropathic pain 
and other forms of severe pain (Taylor et al., 2000; Toombs & Kral, 2005; Jackman, Purvis, & 
Mallett, 2008; Fredheim, Moksnes, Borchgrevink, Kaasa, & Dale, 2009); and (3) a first-line 
treatment in patients with both opioid dependence and chronic pain (Kahan, Srivastava, Wilson, 
Mailis-Gagnon, & Midmer, 2006).  
Methadone has contributed to a significant portion of opioid-related overdose deaths. 
However, this outcome is not attributed to the use of methadone for opioid dependence, rather 
from prescriptions of methadone for pain management (Jones, Baldwin, Manocchio, White, & 
Mack, 2016). Reports from the Centers for Disease Control and Prevention (CDC) indicate a 
15.6% increase in opioid death rates from 2014 to 2015. Conversely, methadone death rates 
decreased by 9.1% due to factors such as efforts to reduce methadone therapy for pain, warning 
labels, clinical guidelines, and limiting high dose formulations (Rudd, Seth, David, & Scholl, 
2016). However, death rates continued to increase through 2014 resulting from methadone 
overdosing in individuals between the ages of 55 – 64 years (Jones et al., 2016).  
Concentrations of (R)- and (S)-methadone above therapeutic levels have negative and 
detrimental side effects. Elevated (R)-methadone levels may depress ventilation, inducing 
respiratory depression, by acting on the MORs expressed on respiratory centers in the brainstem 
(Mitchell et al., 2004; Silverman, Nettleton, Spencer, Wallisch, & Olsen, 2009; van der Schier, 
Roozekrans, van Velzen, Dahan, & Niesters, 2014). Conversely, an increase in (S)-methadone 
disposition causes cardiotoxicity through the blockage of the voltage-gated potassium channel of 
5 
the human ether-a-go-go related gene (hERG), subsequently prolonging the QT interval of an 
electrocardiogram leading to torsades de pointes. (S)-Methadone is 3.5 times more potent than 
(R)-methadone in blocking the hERG channel, thus attributing the stereoselectivity of methadone 
to cardiotoxicity (Eap et al., 2007; Ansermot et al., 2010; Dobrinas et al., 2013; Csajka, Crettol, 
Guidi, & Eap, 2016).  
Methadone is primarily eliminated via hepatic metabolism by cytochrome P450 (CYP) 
enzymes through oxidative biotransformation. Methadone undergoes stereoselective N-
demethylation followed by spontaneous cyclization to form the principle, inactive metabolite 2-
ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) (Figure 1) (Moody, Alburges, Parker, 
Collins, & Strong, 1997; Oda & Kharasch, 2001; Ferrari, Coccia, Bertolini, & Sternieri, 2004; 
Nanovskaya et al., 2004; Lehotay et al., 2005; Lugo, Satterfield, & Kern, 2005). Methadone has 
a broad half-life of elimination ranging from 5 – 130 hours, with an average of 22 hours (Eap, 
Buclin, & Baumann, 2002). This extreme inconsistency in the elimination half-life exemplifies 
the large variability methadone possesses in its pharmacokinetics between individuals. Because 
of the interindividual variation, it is difficult to predict an individual’s peak plasma levels, which 
may result in some individuals having a higher than normal plasma level that approaches the 
toxic or even fatal drug concentration. Comedication, age, gender, health, weight, and ethnicities 
can all be factors that contribute to this effect.  
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Figure 1: Eleven Methadone Metabolites Found in Human Excretion. 
* Indicates chiral carbon atom. ADH, alcohol dehydrogenase; CYP, cytochrome P450; EDDP, 2-ethyl-1,5-dimethyl-3,3- 
diphenylpyrrolidine; EMDP, 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline; p-HO, para-hydroxy.
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Genetic variation occurs within and among populations, leading to polymorphisms. SNPs 
are the most common type of genetic variation. A SNP is a variation of a single nucleotide at a 
specific position in the genome, some of which may contribute to changes in a gene, either in the 
coding (exons) or non-coding (introns) regions, or the regions between genes. A genetic 
variation within CYP genes responsible for the metabolism of methadone may be causal for 
altered function, which may result in methadone being rapidly eliminated from the body, thus 
preventing the drug from reaching therapeutic levels. Alternatively, the genetic variation may 
prolong elimination from the body, consequently, intensifying analgesic and detrimental adverse 
effects (Daly, 2004; Smith, 2009). The purpose of this review is to focus on the effects of SNPs 
of the various CYPs that metabolize methadone. 
1.2 Methadone Metabolism 
Eleven metabolites from methadone metabolism have been isolated and identified in 
urine and feces in humans (Dinis-Oliveira, 2016). Methadone predominantly forms the 
pharmacologically inactive pyrrolidine metabolites EDDP and 2-ethyl-5-methyl-3,3-diphenyl-1-
pyrroline (EMDP). Methadol and normethadol are active analgesic metabolites of methadone, 
although this pathway is relatively minor (Sullivan & Due, 1973; Anggård et al., 1975). To a 
lesser extent, methadone, normethadol, EDDP, and EMDP are further hydrolyzed to form 
inactive p-hydroxy metabolites. Another minor pathway yields the inactive metabolites 4-
dimethylamino-2,2-diphenylvaleric acid, 4-methylamino-2,2- diphenylvaleric acid, and 1,5-
dimethyl-3,3-diphenyl-2-pyrrolidone (Figure 1) (Sullivan & Due, 1973; Anggård et al., 1975; 
Dinis-Oliveira, 2016).  
The CYP enzymes involved in the formation of methadone metabolites in humans are 
CYP2B6, 3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2 
8 
(Chang, Fang, Lin, & Moody, 2011). These CYPs, however, metabolize methadone in a 
stereoselective manner, where CYP2C19, 3A7, and 2C8 preferentially metabolize (R)-
methadone, CYP2B6, 2D6, and 2C18 primarily metabolize (S)-methadone, and CYP3A4 
demonstrates no stereoselectivity in methadone metabolism (Chang et al., 2011; Lemke, 
Williams, Roche, & Zito, 2012). Methadone is N-demethylated to an intermediate compound, 
normethadone, which is then spontaneously cyclized to form EDDP. A second N-demethylation 
reaction occurs on EDDP to form EMDP (Sullivan & Due, 1973; Oda & Kharasch, 2001; Ferrari 
et al., 2004; Nanovskaya et al., 2004; DePriest, Puet, Holt, Roberts, & Cone, 2015). An alternate 
metabolic pathway in the formation of EMDP is a CYP mediated N-demethlyation of 
normethadone to form dinormethadone, which is then spontaneously cyclized to EMDP (Lemke 
et al., 2012). In a minor biotransformation pathway, the keto group of methadone is reduced by 
alcohol dehydrogenase to form methadol, which can be N-demethylated to form normethadol. 
The inactive (S)-methadone produces active metabolites of -l-methadol and -l-normethadol, 
which have analgesic properties comparable to (R)-methadone. (R)-Methadone, on the other-
hand, is metabolized to biologically inactive metabolites of d-methadol and d-normethadol 
(Sullivan & Due, 1973; Anggård et al., 1975; Lemke et al., 2012). 
Methadone’s long ranging half-life can be partially attributed to the extreme 
interindividual pharmacokinetics and its stereoselective metabolism (Leshner, 1997; Boulton, 
Arnaud, & DeVane, 2001). (S)-Methadone exhibits a significantly shorter elimination half-life 
than (R)-methadone (Kristensen et al., 1996; DePriest et al., 2015). Inherited polymorphisms in 
CYPs have the potential to affect the metabolic rate of methadone in a stereoselective manner. 
The following sections will discuss the role of CYP SNPs in methadone metabolism and its 
consequences on biological activity. 
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1.3 Cytochrome P450 (CYP) 
There are approximately 57 active human CYP genes grouped into 18 families and 44 
subfamilies. Only 12 CYP enzymes, which belong to the CYP1, CYP2, or CYP3 families, are of 
major importance and responsible for the metabolism of more than 95% of therapeutic drugs 
(Wang & Tompkins, 2008; Wang, Li, & Zhou, 2009; Zanger & Schwab, 2013). The involvement 
and contribution of SNPs is inadequately understood in drug biotransformation, but are known to 
play a vital role in the differences in patient outcome and the development of personalized 
medicine (Solus et al., 2004). SNPs can cause a loss of function mutation, in which the splicing, 
expression, or transcription of the CYP gene is decreased or the protein structure is altered. 
Alternatively, gain of function mutations may also occur, resulting in an increased substrate 
turnover due to an increased number of functional gene copies, as well as variations in the 
promotor or amino acids (Johansson & Ingelman-Sundberg, 2008; Sadee et al., 2011; Zanger & 
Schwab, 2013). SNPs may be responsible for determining metabolic phenotype – ultra-rapid 
metabolizers (UMs), extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor 
metabolizers (PMs) – and the binding affinity to CYPs, all while affecting the half-life, as well as 
the therapeutic and detrimental effects of methadone. 
1.3.1 CYP1 Family 
The CYP1 family consists of two subfamilies, encompassing three functional genes, 
CYP1A1, 1A2, and 1B1. CYP1A1 and CYP1B1 enzymes are mainly expressed extra-hepatically, 
whereas CYP1A2 accounts for 4-16% of the hepatic CYPs and is responsible for 8-10% of the 
drugs metabolized by CYP isoforms, including methadone (Daly, 2004; McGraw & Waller, 
2012; Zanger & Schwab, 2013).  
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The interindividual variations in the mRNA and protein expression levels of CYP1A2 
range from 15-40 fold, and a 40-130 fold interindividual difference in activity (Zhou, Liu, & 
Chowbay, 2009). To date, there are 192 genetic variants in CYP1A2 (Fokkema et al., 2011; 
Fokkema & den Dunnen, 2017). An in silico study, by Wang et al. (2009), found 31 
nonsynonymous SNPs, of which 24 were predicted to be deleterious by the SIFT and PolyPhen 
algorithms. (S)-Methadone is marginally metabolized by CYP1A2 (Zhou et al., 2009; Chang et 
al., 2011). However, results of an in vitro study, conducted by Wang and DeVane (2003), show 
neither the depletion of (R)- and (S)-methadone, nor the formation of EDDP by recombinant 
CYP1A2. Genetic variations in CYP1A2 did not affect or had little influence on the plasma 
concentrations of methadone and EDDP (Fredheim et al., 2009; Zhou et al., 2009; Chang et al., 
2011). Additionally, Crettol et al. (2006) observed CYP1A2*1F did not influence (R)-, (S)-, or 
(R,S)-methadone at the peak or trough levels in 245 MMT patients (96% white) (Table 1). Based 
on the current studies, CYP1A2 SNPs have not been shown to impact the metabolism of 
methadone.  
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Alleles dbSNP ID† Key sequence 
change‡ 
Effect and key amino acid 
substitution (if any) 
Effect on enzyme activity§ 
CYP1A2*1F rs762551 intron 1, c.-9-
154C>A 
 No influence on (R)-, (S)-, or (R,S)-MTD 
levels at trough or peak 
CYP2B6*2 rs8192709 c.64C>T R22C  [(R,S)-MTD]/[EDDP] ratio 
CYP2B6*4 rs2279343 c.785A>G K262R  (R,S)-MTD plasma levels 
 (R,S)-MTD plasma levels 
 MTD clearance 
 (R)- and (S)-MTD N-demethylation 
CYP2B6*5 rs3211371 c.1459C>T R487C  (S)-MTD plasma levels 
 (S)-MTD clearance 
No effect on MTD clearance 
 (R,S)-MTD plasma levels 
CYP2B6*6 rs2279343 
rs3745274 
c.785A>G 
c.516G>T 
K262R 
Q172H 
 (S)- and (R,S)-MTD plasma levels 
 MTD/Dose plasma ratio 
 (R)- and (S)-MTD N-demethylation 
 MTD clearance 
CYP2B6*9 rs3745274 c.516G>T Q172H  (R,S)-MTD plasma levels  
 [(S)-MTD/MTD Dose] plasma ratio 
 (R)- and (S)-MTD N-demethylation  
 (S)-MTD clearance 
CYP2B6*11 rs35303484 c.136A>G M46V  (S)-MTD plasma levels 
 (S)-MTD clearance 
CYP2B6 
3’UTR 
rs707265 c.*1355A>G   [(S)-MTD/MTD Dose] plasma ratio 
 (S)-MTD clearance 
CYP2B6 
3’UTR 
rs1038376 3’UTR, 
c.*1277A>T 
  [(S)-MTD/MTD Dose] plasma ratio 
 (S)-MTD clearance 
CYP2B6 
intron 1 
rs10403955 c.172-468T>G   [(S)-MTD/MTD Dose] plasma ratio 
 (S)-MTD clearance 
CYP2B6 
intron 5 
rs2279345 c.923-197T>C   [(S)-MTD/MTD Dose] plasma ratio 
 (S)-MTD clearance 
CYP2C9*2 rs1799853 c.430C>T R144C No effect on MTD plasma levels 
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Alleles dbSNP ID† Key sequence 
change‡ 
Effect and key amino acid 
substitution (if any) 
Effect on enzyme activity§ 
 MTD/ Dose plasma ratio 
CYP2C9*3 rs1057910 c.1075A>C I359L No effect on MTD plasma levels 
 MTD/Dose plasma ratio 
CYP2C19*2 rs4244285 c.681G>A I331V; splicing defect No effect on MTD plasma levels 
 (R)-MTD plasma levels 
 MTD/Dose plasma ratio 
 EDDP plasma levels 
CYP2C19*3 rs4986893  c.636G>A W212X; stop codon No effect on MTD plasma levels 
 MTD/Dose plasma ratio 
CYP3A4*1B rs2740574 5’UTR, 
c.-392A>G 
  (S)-MTD plasma levels 
CYP3A5*3 rs776746 5’UTR, 
c.219-237A>G 
Splicing defect No effect on MTD plasma levels 
 MTD metabolism (*1/*3 carrier) 
 MTD/Dose plasma ratio (*3/*3)  
Table 1: Cytochrome P450 Single Nucleotide Polymorphisms Relevant to Methadone Metabolism 
† National Center for Biotechnology Information (NCBI) dbSNP (NCBI Resource Coordinators, 2016) 
‡ Location of sequence change on mRNA for the respective CYP NM accession number (NCBI Resource Coordinators, 2016) 
§ (Crettol et al., 2005; Crettol et al., 2006; De Fazio et al., 2008; Fonseca et al., 2011; Wang et al., 2011; Dobrinas et al., 2013; Gadel 
et al., 2013; Kharasch & Stubbert, 2013; Lee et al., 2013; Levran et al., 2013; Wang et al., 2013; Carlquist et al., 2015; Gadel et al., 
2015; Kharasch et al., 2015; Ahmad et al., 2017; Kringen et al., 2017) 
More comprehensive information is available from the Human Cytochrome P450 Allele Nomenclature Committee (Zhou et al., 2017) 
CYP, cytochrome P450; MTD, methadone; EDDP, 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine; UTR, untranslated region. 
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1.3.2 CYP2 Family 
The CYP2 family represents about 30% of human CYP isoforms, making it the largest 
CYP family (Kim et al., 2015; Daly, 2016). The liver is comprised of five drug metabolizing 
CYP2 subfamilies (A-E), of which, the most pharmacologically important genes display the 
highest levels of polymorphism (Zanger & Schwab, 2013; Solus et al., 2004). Methadone is 
metabolized by several members of the CYP2 family: 2B6, 2C8, 2C9, 2C18, 2C19, and 2D6. 
1.3.2.1 CYP2B 
CYP2B6 has a 1-10% contribution to the total hepatic CYP pool, accounting for the 
metabolism of about 7-8% of pharmaceutical drugs (Zhou et al., 2009; Zanger & Schwab, 2013). 
Despite this enzyme’s relatively low involvement in drug metabolism, CYP2B6 is the 
predominant determinant involved in the N-demethylation of methadone and clearance. CYP2B6 
also displays stereoselectivity towards (S)-methadone (Chang et al., 2011; Kharasch & Stubbert, 
2013). CYP2B6 is one of the most polymorphic genes, having 74 allelic variants and 38 protein 
variants, which affect catalytic activity, transcriptional regulation, and splicing. The variants also 
affect mRNA and protein expression, exhibiting nearly 300 fold interindividual variability 
(Fokkema et al., 2011; Zanger & Klein, 2013; Zanger & Schwab, 2013; Ingelman-Sundberg, 
2017; Zhou, Ingelman-Sundberg, & Lauschke, 2017; Fokkema & den Dunnen, 2018a).  
CYP2B6 SNPs can alter the metabolic ratios of [methadone]/[EDDP]. A significant 
decrease in the metabolic ratio was observed in individuals carrying the CYP2B6*2 allele, 
suggesting a role in an increased rate of metabolism. The data should be interpreted with caution 
because the subjects heterozygous for the variant only had a sample size of two (Ahmad, Sabet, 
Primerano, Richards-Waugh, & Rankin, 2017). A bioinformatics study also predicted CYP2B6*2 
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to alter the metabolic phenotype as determined by both the SIFT and PolyPhen algorithms 
(Wang et al., 2009).  
Lee et al. (2013) studied the influence of CYP2B6*4 on methadone plasma 
concentrations in 178 MMT patients in Taiwan. The study indicated an increase in (R,S)-
methadone plasma levels in individuals homozygous for CYP2B6*4. The results were consistent 
with the Levran et al. (2013) study of 74 Israeli MMT patients; though neither study showed any 
significant differences in the increase in (R,S)-methadone plasma levels. On the other hand, 
Kharasch and colleagues (Kharasch, Regina, Blood, & Friedel, 2015) observed CYP2B6*4 
carriers had a significant decrease in (R)-, (S)-, and (R,S)- methadone plasma levels, with 
increased methadone metabolism and clearance. It is important to note that one of the limitations 
to this study was the small sample size (n=4). Gadel and colleagues (2015) demonstrated an 
increase in N-demethylation of methadone by CYP2B6*4 in an in vitro study, supporting the 
findings of Kharasch et al. (2015). 
CYP2B6*5 shows contradicting data in its involvement in methadone clearance and 
plasma concentrations. In a genotyping study of methadone-only overdoses in 125 Caucasians, 
CYP2B6*5 was linked to a significant increase in (R,S)-methadone plasma levels (Ahmad et al., 
2017). In a study cohort consisting of 35 individuals with low (S)-methadone levels, CYP2B6*5 
was overrepresented, indicating an increased CYP2B6 activity (Dobrinas et al., 2013). The 
methadone plasma concentration of two individuals genotyped for homozygosity in CYP2B6*5 
appeared to remain unaltered when compared to that of the wild type CYP2B6*1 (Kharasch et 
al., 2015).  
CYP2B6*6 is a haplotype consisting of two nonsynonymous variants, CYP2B6*4 and 
CYP2B6*9. Numerous papers indicate an increase in (R,S)- and (S)-methadone plasma levels in 
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CYP2B6*6/*6 individuals (Crettol et al., 2005; Crettol et al., 2006; Kharasch & Stubbert, 2013; 
Kharasch et al., 2015; Kringen et al., 2017). Gadel and colleagues (Gadel, Crafford, Regina, & 
Kharach, 2013) and Kharasch et al. (2015) have also demonstrated a decrease in methadone N-
demethylation and decreased methadone clearance, respectively. An in vitro study found SNPs 
CYP2B6*6 and CYP2B6*9 to be catalytically deficient in EDDP formation (Gadel, Friedel, & 
Kharasch, 2015). Furthermore, increased (R,S)-methadone plasma levels were observed in 74 
Israeli MMT patients homozygous for the CYP2B6*9 SNP, though the increase was not 
statistically significant (Levran et al., 2013). A significant increase in plasma concentrations and 
a decrease in (S)-methadone metabolism was observed in 366 Taiwanese MMT patients 
encompassing the CYP2B6*9 SNP (Wang et al., 2011). The studies observing the SNPs of the 
haplotype CYP2B6*6 suggest that the diminishing metabolic activity of CYP2B6*6/*6 is 
credited to the c.516G>T variant of CYP2B6*9. 
Dobrinas et al. (2013) observed an overrepresentation of CYP2B6*11 polymorphism in a 
high (S)-methadone level group of MMT patients, indicating a decline in CYP2B6 activity. 
Wang et al. (2011) examined polymorphisms in the intronic and 3’-untranslated region (UTR) 
regions of CYP2B6, and demonstrated the SNPs rs707265, rs2279345, rs1038376, and 
rs10403955 all correspond to increased [(S)-methadone/methadone dose] plasma ratios, and 
decreased (S)-methadone clearance (Table 1). The SNPs investigated in this section demonstrate 
a compelling link to the importance of genetic variations in CYP2B6 and altered metabolism of 
methadone.  
1.3.2.2 CYP2C  
The CYP2C subfamily consists of four genes, CYP2C8, 2C9, 2C18, and 2C19. The CYPs 
from these genes all contribute to the metabolism of methadone (Iribarne et al., 1996; Crettol et 
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al., 2005; Chang et al., 2011; Fonseca et al., 2011). CYP2C9 is the highest expressed isozyme of 
the four in liver, while CYP2C8 and CYP2C19 are expressed at 2 and 10 fold lower levels than 
CYP2C9 (Zanger & Schwab, 2013). CYP2C18 is expressed primarily in the skin (Zhou et al., 
2009). CYP2C19 comprises 16% of the CYP2C family and metabolizes methadone to a greater 
extent, as compared to the CYP2C8, 2C9, and 2C18 isozymes (Dinis-Oliveira, 2016). The 
CYP2C family demonstrates stereoselectivity in methadone metabolism, where CYP2C8 and 
2C19 predominately metabolize (R)-methadone, while CYP2C18 primarily metabolizes (S)-
methadone.  
Currently, there are no polymorphic studies on CYP2C8 and 2C18 and their role in 
methadone metabolism. This is not surprising for CYP2C18, where only 8 variants have been 
reported to date (Fokkema et al., 2011; Fokkema & den Dunnen, 2015a). There are 97 genetic 
variants observed in CYP2C8 (Fokkema et al., 2011; Fokkema & den Dunnen, 2015b), which 
has a minor role in the metabolism of methadone, probably contributing to the dearth of studies 
in the corresponding SNPs.  
Although CYP2C9 exhibits 378 genetic variants and 2C19 has 236 reported genetic 
variants (Fokkema et al., 2011; Fokkema & den Dunnen, 2018b; Fokkema & den Dunnen, 
2019), only *2 and *3 have been examined for their respective CYP isozymes. Results from 
three separate studies showed no effect on methadone plasma levels with CYP2C9*2 and 
CYP2C9*3 genotypes in Caucasians (Crettol et al., 2005; Crettol et al., 2006; Fonseca et al., 
2011). A significant increase in methadone serum concentrations/dose ratio with heterozygous 
carriers of CYP2C9*2 and CYP2C9*3 SNPs was observed in a study in Norway. Similar results 
were seen for the homozygous CYP2C9*2 and CYP2C9*3 individuals, albeit, there were no 
significant differences in methadone serum concentrations/dose ratios (Kringen et al., 2017).  
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In studies by Crettol et al. (2005; 2006), CYP2C19*2 and CYP2C19*3 were also found to 
lack an effect on methadone plasma levels. A study of 366 Taiwanese MMT patients showed 
homozygous carriers of CYP2C19*2 were associated with a significant increase in (R)- 
methadone levels. Patients homozygous for CYP2C19*3 also tended to exhibit an increase in 
(R)-methadone levels, although the data was not significantly different (Wang et al., 2013). 
Carlquist et al. (2015) observed an increase in the plasma levels of EDDP with CYP2C19*2 in 
25 MMT patients (20 Caucasian, 4 Hispanic, and 1 African American), indicating an increase in 
methadone metabolism. Kringen et al. (2017) noticed, in a Norwegian population, individuals 
homozygous and heterozygous carriers for CYP2C19*2 and CYP2C19*3 had an increase in 
methadone serum concentration/dose ratio, with significant differences seen only in 
heterozygotes. The contradicting results in the CYP2C19 variants between these studies could be 
attributed to the ethnicity of the patients, where the frequencies of both CYP2C19*2 and 
CYP2C19*3 are higher in Asians than Caucasians (Table 1).  
1.3.2.3 CYP2D  
The CYP2D subfamily consists of only one protein coding gene, CYP2D6, which 
accounts for 2-5% of the hepatic CYP composition and ~25% of pharmacological drug 
metabolism (Zanger & Schwab, 2013; NCBI Resource Coordinators, 2016). CYP2D6 
metabolizes both enantiomers of methadone, with a slightly greater propensity towards (S)-
methadone (Wang & DeVane, 2003; Chang et al., 2011). Unlike SNPs in other CYP genes, 
CYP2D6 phenotype is determined by allele combinations. PMs consist of two non-functional 
alleles, IMs are comprised of two decreased activity alleles, EMs have at least one functional 
allele, and UMs encompass more than one functional allele and/or an allele with a promoter 
mutation (Fonseca et al., 2011). The major and most common mutation alleles are CYP2D6*3, 
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*4, *5, and *6, accounting for 93-97% of alleles among PM phenotypes (Eap et al., 2001; 
Trescot & Faynboym, 2014). CYP2D6*1 and CYP2D6*2 alleles represent normal functional 
activity.  
In a 2001 study conducted by Eap et al. (2001), CYP2D6 phenotypes had a significant 
influence on the (R)-, (S)-, and (R,S)-methadone blood concentrations, where higher 
concentrations were observed in PMs (CYP2D6*4/*4, *4/*3, *4/*6) and lower concentrations 
were measured in UMs (CYP2D6*1/*1). Similarly, Crettol and colleagues (2006), observed a 0.5 
fold decrease in (S)-methadone and 0.7 fold decrease in (R)-methadone plasma levels in UMs 
(CYP2D6*1/*1xN) when compared to the EM/IM (CYP2D6*1/*3, *1/*4, *1/*5, *1/*6) group. In 
another study, the PM, IM, and EM phenotypes, representing alleles CYP2D6*1, *1xN, *2, *3, 
*4, *4xN, *5, *6, *9, *10, *16, *28, *33, and *41, did not impact the clearance of (R)-, (S)-, or 
(R,S)-methadone (Coller et al., 2007). CYP2D6*3, *4, *5, *6, *7, and *8 are non-functional 
variants, and CYP2D6*9, *10, and *41 have a decrease in function (Coller et al., 2007). Fonseca 
et al. (2011) observed EM patients received significantly lower doses of methadone as compared 
to UMs. It was also concluded that, contradictory to the phenotypes, UM (CYP2D6*1xN, *2xN) 
patients had significantly higher methadone plasma levels than EM (CYP2D6*1, *2, *3, *6, *35) 
and PM (CYP2D6*4/*4) patients. Further investigations on the CYP2D6 alleles need to be 
conducted to get a clearer understanding of their significance. The relationship between CYP2D6 
allelic variants and phenotypic expression is depicted in Table 2. 
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Alleles dbSNP ID† Key sequence 
change‡ 
Effect and key amino acid 
substitution (if any) 
Effect on enzyme activity§ Phenotype 
CYP2D6*1    Wild type 
Duplication of gene 
EM 
CYP2D6*1xN    Multiduplication of gene 
N active genes 
 activity 
UM 
CYP2D6*2 rs16947 
rs1135840 
c.886C>T 
c.1457G>C 
R296C 
S486T 
Normal activity 
Duplication of gene 
EM 
CYP2D6*2xN    Multiduplication of gene 
N active genes 
 activity 
UM 
CYP2D6*3 rs3574686 c.775delA 259Frameshift Defective allele PM 
CYP2D6*4 rs1065852 
rs28371703 
rs28371704 
rs3892097 
rs1135840 
c.100C>T 
c.271C>A 
c.281A>G 
c.506-1G>A 
c.1457G>C 
P34S 
L91M 
H94R 
Splicing defect 
S486T 
Defective allele PM 
CYP2D6*4xN    Defective allele 
Multiduplication of gene 
 
PM 
CYP2D6*5    Deletion of entire CYP2D6 
gene 
PM 
CYP2D6*6 rs5030655 c.454delT 118Frameshift Defective allele PM 
CYP2D6*7 rs5030867 c.971A>C H324P Defective allele PM 
CYP2D6*8 rs5030865 
rs16947 
rs1135840 
c.505G>A 
c.886C>T 
c.1457G>C 
G169R 
R296C 
S486T 
Defective allele PM 
CYP2D6*9 rs5030656 c.841_843delAAG K281del Impaired function IM 
CYP2D6*10 rs1065852 
rs1135840 
c.100C>T 
c.1457G>C 
P34C 
S486T 
Impaired function IM 
CYP2D6*16  CYP2D7/2D6 hybrid Frameshift; switch region 
exon7-intron 8 
 PM 
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Alleles dbSNP ID† Key sequence 
change‡ 
Effect and key amino acid 
substitution (if any) 
Effect on enzyme activity§ Phenotype 
CYP2D6*17 rs28371706 
rs16947 
rs1135840 
c.320C>T 
c.886C>T 
c.1457G>C 
T107I 
R296C 
S486T 
Impaired function IM 
CYP2D6*28  
rs78482768 
rs16947 
rs1135840 
19G>A 
c.451C>G 
c.886C>T 
c.1457G>C 
V7M 
Q151E 
R296C 
S486T 
Unknown Unknown 
CYP2D6*29 rs61736512 
rs16947 
rs59421388 
rs1135840 
c.406G>A 
c.886C>T 
c.1012G>A 
c.1457G>C 
V136I 
R296C 
V338M 
S486T 
Impaired function IM 
CYP2D6*33 rs28371717 c.709G>T A237S Normal activity EM 
CYP2D6*35 rs769258 
rs16947 
rs1135840 
c.31G>A 
c.886C>T 
c.1457G>C 
V11M 
R296C 
S486T 
Normal activity 
Duplication of gene 
EM 
CYP2D6*36 rs1065852 
rs1135840 
c.100C>T 
c.1457G>C 
P34S 
S486T 
Defective allele PM 
CYP2D6*41 rs16947 
rs28371725 
rs1135840 
c.886C>T 
c.985+39G>A 
c.1457G>C 
R296C 
Splicing defect 
S486T 
Impaired function IM 
CYP2D6*43 rs28371696 c.77G>A R26H Normal activity 
Duplication of gene 
EM 
CYP2D6*45 rs28371710 
rs16947 
rs1135840 
c.463G>A 
c.886C>T 
c.1457G>C 
E155K 
R296C 
S486T 
Normal activity 
Duplication of gene 
EM 
Table 2: Cytochrome P450 2D6 and Their Corresponding Activity and Phenotype 
† National Center for Biotechnology Information (NCBI) dbSNP (NCBI Resource Coordinators, 2016) 
‡ Location of sequence change on mRNA for the respective CYP NM accession number (NCBI Resource Coordinators, 2016) 
§ (Eap et al., 2001; Crettol et al., 2006; Coller et al., 2007; Johansson & Ingelman-Sundberg, 2008; Fonseca et al., 2011) 
More comprehensive information is available from the Human Cytochrome P450 Allele Nomenclature Committee (Zhou et al., 2017) 
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CYP, cytochrome P450; del, deletion; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultra-
rapid metabolizer. 
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1.3.3 CYP3 Family 
The CYP3 family consists of only one subfamily, CYP3A, and four functional genes, 
CYP3A4, 3A5, 3A7, and 3A43. These enzymes play a dominant role in drug metabolism 
pathways (~50%). CYP3A4 is the most expressed enzyme in adult liver, while CYP3A7 is 
predominantly expressed in fetal liver and is down-regulated after birth. CYP3A5 is 
polymorphically expressed in the liver, where alternative splicing results in multiple transcript 
variants, exhibiting high and low level proteins (Lamba, Lin, Schuetz, & Thummel, 2012; 
Zanger & Schwab, 2013; NCBI Resource Coordinators, 2016).  
Methadone has been shown to be N-demethylated by CYP3A4, 3A5, and 3A7 in a 
nonstereoselective manner (Foster, Somogyi, & Bochner, 1999; Chang et al., 2011). CYP3A4 
and CYP3A5 have relatively low numbers of genetic variants, suggesting minor clinical 
importance in the clearance of their respective substrates (Zhou et al., 2009; Levran et al., 2013). 
This observation would be in line with the lack of polymorphic studies found for CYP3A and 
their role in methadone metabolism. However, in one study, the allelic frequency of CYP3A4*1B 
in 245 MMT patients (96% white) was observed and correlated with an increase in methadone 
plasma levels (Crettol et al., 2006). In the same study, the study cohort was genotyped for the 
deficient allele CYP3A5*3. The plasma levels of methadone were not influenced by the CYP3A5 
genotype. It is also interesting to note that there was a strong linkage between CYP3A4*1B and 
CYP3A5*3 genotypes (Crettol et al., 2006). Similar results were observed by Fonseca, et al. 
(2011), where the genetic polymorphism of CYP3A5 did not influence methadone plasma levels. 
One case report of a 25-year old male in a MMT program showed extensive metabolism of 
methadone to EDDP. The subject was found to be heterozygous for CYP3A5*1 (CYP3A5*1/*3) 
(De Fazio, Gallelli, De Siena, De Sarro, & Scordo, 2008). A large amount of CYP3A5 is 
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expressed in individuals carrying at least one CYP3A5*1 allele (De Fazio et al., 2008). In a 
recent study of 155 serum samples and 62 patients, homozygous carriers of CYP3A5*3 
demonstrated a significant increase in methadone serum concentration/dose ratio, indicating a 
decrease in methadone clearance (Kringen et al., 2017) (Table 1). 
1.4 Consequences of Altered Methadone Metabolism 
Polymorphisms in genes encoding CYP enzymes have the potential to shift their 
metabolic capacity or change the substrate specificity of the enzyme, eliciting variable 
consequences in drug treatment (Jurica & Sulcova, 2012; Tamási & Falus, 2012). These changes 
can be crucial in the therapeutic potency of methadone. The main metabolic pathway of 
methadone involves the N-demethylation by hepatic CYPs into the primary metabolite, EDDP. 
Changes in the rate of EDDP formation could influence the pharmacodynamics of methadone.  
CYP2B6*4 was the only SNP that was found to increase the clearance of methadone by 
the N-demethylation of both (R)- and (S)-methadone (Gadel et al., 2015; Kharasch et al., 2015). 
In turn, there would be a decrease in the disposition of (R,S)-methadone, reducing the 
pharmacological effect of methadone and inducing withdrawal symptoms. Individuals with this 
SNP may require a higher dose of methadone.  
Several SNPs were found to increase the methadone plasma concentration due to a 
decrease in the metabolic activity of the CYPs. Three independent studies collectively 
demonstrated elevated plasma levels of (R,S)- and (S)-methadone with diminishing N-
demethylation of (R)- and (S)-methadone due to CYP2B6*2, *9 and *11 (Wang et al., 2011; 
Dobrinas et al., 2013; Levran et al., 2013; Gadel et al., 2015; Ahmad et al., 2017). CYP2B6*6 is 
a haplotype consisting of both CYP2B6*4 and CYP2B6*9 variants. Carriers of CYP2B6*6/*6 
had diminished methadone metabolism and clearance, hence, an increase in methadone levels. 
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This activity is credited to the CYP2B6*9 SNP, where individuals with CYP2B6*4/*6 haplotype 
did not observe the metabolic inhibition (Crettol et al., 2005; Crettol et al., 2006; Gadel et al., 
2013; Kharasch & Stubbert, 2013; Gadel et al., 2015; Kharasch et al., 2015; Kringen et al., 
2017). Mutations located in the UTR and intronic regions are also relevant in the 
biotransformation of methadone. Table 1 shows the four SNPs in the UTR and intronic regions 
linked to a decreased clearance and increased concentration of methadone (Wang et al., 2011). 
CYP2B6 influences the metabolism of (S)- methadone and, to a far lesser extent, (R)-methadone. 
Individuals with the genotypes mentioned above, particularly CYP2B6*6/*6, have a greater risk 
of suffering torsades de pointes and sudden death. A lower dose of methadone may be required 
for treatment for individuals with these variants.  
Reduced metabolism by CYP2C19 can lead to increased plasma concentrations of 
methadone, specifically (R)-methadone, which can potentiate depressed ventilation manifesting 
as a potentially fatal respiratory depression. Both CYP2C19*2 and CYP2C19*3 were associated 
with elevated methadone plasma concentrations (Wang et al., 2013; Kringen et al., 2017). 
However, these results could be variable in different ethnic groups.  
CYP2D6 and CYP3A4/5 metabolize both enantiomers of methadone, though CYP2D6 
has a slightly greater preference towards (S)-methadone. Decreased metabolism by these CYPs 
may heighten either detrimental effect due to augmented levels of methadone. CYP3A4*1B has 
been shown to increase (S)-methadone plasma levels (Crettol et al., 2006), which can lead to 
cardiotoxic effects. In a study of 136 Caucasian individuals who died of methadone-only 
overdosing, an enrichment was observed in the CYP3A4*1B SNP (Richards-Waugh, Primerano, 
Dementieva, Kraner, & Rankin, 2014). CYP3A5*3 is a common SNP with high frequency in the 
Caucasian population, where a splicing defect causes a loss of function of the CYP3A5 enzyme 
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(McGraw & Waller, 2012). This loss of function is exemplified in a couple of studies where the 
methadone plasma levels are elevated in CYP3A5*3/*3 individuals, while metabolism is 
increased and plasma levels are decreased in individuals carrying at least one copy of CYP3A5*1 
(De Fazio et al., 2008; Gadel et al., 2013). The effects of SNPs located on the CYP2D6 gene is 
slightly more complicated. CYP2D6-dependent metabolism of methadone has been studied 
based on the phenotypic variability determined by a combination of SNPs on the CYP2D6 gene. 
There have not been any clear implications on the relationship between CYP2D6 SNPs and 
methadone metabolism and their role on the pharmacokinetics and pharmacodynamics of 
methadone. 
Since methadone is metabolized by a number of CYPs, a combination of any of the 
SNPs, within or between genes, can have varying effects on the pharmacological response of 
methadone treatment. A genome-wide pharmacogenomic study showed two CYP2B6 haplotypes 
of rs8100458, rs7250601, rs7250991, rs11882424, rs8192719, and rs10853744 (T-A-A-T-C-G 
and T-C-C-T-T-T) accounted for the variation in (S)-methadone plasma levels (Yang et al., 
2016). In order to understand the complexity of the effects of CYP SNPs on methadone 
pharmacokinetics and pharmacodynamics, inclusion of additional gene variants and haplotype 
variants is required. Though SNPs influence only part of methadone pharmacology, the impact 
of genetic variations can be compounded by drug interactions, environmental factors, sex, health, 
and other nongenetic factors. Co-administration of methadone with respiratory depressants, such 
as other opioids, alcohol, or benzodiazepines, may lead to a greater detrimental effect. Likewise, 
individuals with reduced liver function (e.g. cirrhosis) could have a reduced capacity to 
metabolize methadone.  
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1.5 Conclusions 
Methadone is currently used as a treatment and maintenance therapy for opioid addiction 
and as an analgesic for severe chronic pain. The wide-ranging half-life of methadone may result 
in some individuals having higher than normal therapeutic levels leading to negative, 
detrimental, and fatal side effects. Elevated (R)-methadone levels may lead to respiratory 
depression, while an increase in plasma levels of (S)-methadone may lead to severe cardiac 
arrhythmias. A significant portion of opioid-related deaths have been contributed to the use of 
prescription methadone for pain management. The pharmacogenetics of an individual possesses 
the ability to affect the pharmacokinetics and pharmacodynamics of methadone. SNPs located on 
CYP genes shift the metabolic capacity or change the substrate specificity of the CYP enzyme, 
affecting the metabolism of methadone. SNPs CYP2B6*6, *9, *11, CYP2C19*2, *3, 
CYP3A4*1B, and CYP3A5*3 result in increased methadone plasma concentrations, decreased N-
demethylation, and decreased methadone clearance. Since CYP2B6 is the major determinant of 
methadone clearance, CYP2B6*6/*6 is of particular interest. Homozygous carriers of 
CYP2B6*6/*6 expressed diminished methadone metabolism and clearance, thus these 
individuals have a greater propensity for detrimental adverse effects. However, CYP2B6*4 
demonstrated an increase in N-demethylation and methadone clearance. A better understanding 
of the role of CYP SNPs in methadone metabolism can improve the proper therapeutic dosing 
for methadone, patient outcome, and the development of individualized medicine.  
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Abstract 
Cytochrome P450 (CYP) enzyme 2B6 plays a significant role in the stereoselective 
metabolism of (S)- methadone to 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine, an inactive 
methadone metabolite. Elevated (S)-methadone can cause cardiotoxicity by prolonging the QT 
interval of the heart’s electrical cycle. Large interindividual variability of methadone 
pharmacokinetics causes discordance in the relationship between dose, plasma concentrations 
and side effects. The purpose of this study was to determine if one or more single nucleotide 
polymorphisms (SNPs) located within the CYP2B6 gene contributes to a poor metabolizer 
phenotype for methadone in these fatal cases. The genetic analysis was conducted on 125 
Caucasian methadone-only fatalities obtained from the West Virginia and Kentucky Offices of 
the Chief Medical Examiner. The frequency of eight exonic and intronic SNPs (rs2279344, 
rs3211371, rs3745274, rs4803419, rs8192709, rs8192719, rs12721655 and rs35979566) was 
determined. The frequencies of SNPs rs3745274 (*9, c.516G>T, Q172H), and rs8192719 
(21563C>T) were enhanced in the methadone-only group. Higher blood methadone 
concentrations were observed in individuals who were genotyped homozygous for SNP 
rs3211371 (*5, c.1459C>T, R487C). These results indicate that these three CYP2B6 SNPs are 
associated with methadone fatalities. 
2.1 Introduction 
Initially discovered and developed in Germany during World War II, methadone is a 
synthetic MOR agonist that has been used as an analgesic alternative to morphine when it was 
difficult to obtain (Lugo et al., 2005; Lisberg & Scheinmann, 2013; Somogyi et al., 2014). In 
1965, methadone was introduced as a treatment regimen of opioid drug dependence or 
withdrawal symptoms in patients (Somogyi et al., 2014). Nearly a decade later, in 1976, 
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physicians were given permission to prescribe methadone as an analgesic to maintain adequate 
pain control (Toombs & Kral, 2005), for malignant pain in cancer patients and non-malignant 
pain that continues beyond the normal course of a disease or injury (Taylor et al., 2000; Jackman 
et al., 2008). 
Methadone is clinically available in the USA only as a racemic mixture containing equal 
amounts of the (R)- and (S)-methadone enantiomers (Gaertner et al., 2008; Kapur et al., 2011; 
McCance-Katz, 2011). Each enantiomer has specific pharmacodynamic properties. The analgesic 
properties of methadone are attributed to the (R)-enantiomer, which has a 10-fold greater affinity 
for the MOR (Kristensen, Christensen, & Christrup, 1995; Foster et al., 1999) and is 8 – 50 times 
more potent than (S)-methadone (Lugo et al., 2005). As concentrations of (R)-methadone 
increase above therapeutic levels, negative side effects on MORs in the brainstem respiratory 
centers can be potentiated, thus mediating respiratory depression (Mitchell et al., 2004; 
Silverman et al., 2009). On the other hand, elevated (S)-methadone causes cardiotoxicity by 
prolonging the QT interval and subsequently leads to torsade de pointes by blocking the voltage-
gated potassium channel of the human ether-a-go-go related gene (hERG) (Eap et al., 2007; 
Dobrinas et al., 2013). This stereoselective cardiotoxicity is attributed to (S)-methadone being 
3.5 times more potent than (R)- methadone in blocking the hERG channel (Eap et al., 2007; 
Ansermot et al., 2010; Dobrinas et al., 2013). 
Methadone metabolism occurs primarily through the route of oxidative 
biotransformation. The principle metabolite, EDDP, is formed during metabolism through an N-
demethylation reaction followed by spontaneous cyclization (Moody et al., 1997; Foster et al., 
1999; Ferrari et al., 2004; Nanovskaya et al., 2004; Lehotay et al., 2005). EDDP is further 
metabolized to EMDP. Neither of these metabolites is pharmacologically active (Oda & 
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Kharasch, 2001; Ferrari et al., 2004; Nanovskaya et al., 2004). CYP enzymes in the liver are 
responsible for the metabolism of methadone, which undergoes stereoselective N-demethylation 
(Lugo et al., 2005). CYP3A4, 2B6 and 2C19 account for majority of the conversion of 
methadone to EDDP and other inactive metabolites, with minor contributions from CYP2C8, 
2D6, 2D8, 2C18 and 3A7 (Wang & DeVane, 2003; Chang et al., 2011; Kapur et al., 2011). (R)-
Methadone is preferentially metabolized by CYP2C8 and CYP2C19, whereas (S)-methadone is 
primarily metabolized by CYP2B6 and CYP2D6. CYP3A4 has no stereoselectivity, 
metabolizing both enantiomers (Chang et al., 2011; Kapur et al., 2011). 
Methadone is a difficult medication to safely prescribe due to extreme variability in 
interindividual pharmacokinetics, making the relationship between dose, plasma concentrations 
and effects difficult to define (Leshner, 1997; Boulton et al., 2001). This methadone plasma 
variability increases the risk of an unexpected death. According to the most recent CDC report 
(2012), methadone accounts for >30% of prescription opioid deaths, while it only represents 2% 
of all opioid prescriptions. Much of the interindividual variability in methadone 
pharmacokinetics may be due to genetic variations within the genes encoding CYP enzymes 
responsible for the metabolism of methadone (Li et al., 2008). 
SNPs are the most common form of genetic variation in the CYP genes (Risch, 2000; 
Daly, 2004). CYP2B6 is a highly polymorphic gene with 74 allelic variants equating to 38 
protein variants and a series of subvariants, designated *1B to *38 (Zhou et al., 2009; McGraw & 
Waller, 2012; Ingelman-Sundberg, 2017; Fokkema & den Dunnen, 2018a). These SNPs are 
thought to play a role in interindividual and interethnic differences in the response of drug 
metabolism by CYP2B6 (Zhou et al., 2009). It is known that CYP2B6 plays a major role in the 
biotransformation of many clinically important drugs, such as selegiline (Watanabe et al., 2010), 
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bupropion (Lang et al., 2004), efavirenz (Holzinger et al., 2012), artemether (Honda et al., 2011) 
and methadone (Eap et al., 2007; Ansermot et al., 2010; Dobrinas et al., 2013). These studies 
demonstrated that some allelic variants (e.g., rs2279344, rs3211371, rs3745274, rs4803419, 
rs8192709, rs8192719, rs12721655 and rs35979566) lead to a decreased expression or decreased 
enzyme activity of CYP2B6. 
Several pharmacogenetic studies have been previously conducted involving methadone-
related deaths or patients in a MMT program. However, these studies did not include cases 
where only methadone was detected; rather, those studies used mixed drug cases and/or had 
small sample sizes (Crettol et al., 2005; Eap et al., 2007; Dobrinas et al., 2013). The present work 
is unique because we genotyped and analyzed CYP2B6 variants in 125 Caucasians involved with 
methadone-only fatalities. Eight key SNP variants present in the Caucasian population were 
genotyped to test for enrichment. The analyses performed in this study were aimed to provide 
insight into the association of CYP2B6 SNPs in individuals who succumb to methadone 
intoxication in the methadone-only cases. Because exonic variants cause amino acid 
substitutions, which can affect the enzymatic activity and intronic regions, are responsible for 
splicing, frameshifting and binding microRNAs, SNPs in both of these regions were examined to 
determine their association with methadone toxicity in the study population. 
2.2 Material and Methods 
2.2.1 Chemicals and Enzymes 
QIAamp DNA Micro extraction kits were purchased from Qiagen (Valencia, CA, USA). 
Absolute ethanol was purchased from Pharmco-Aaper (Shelbyville, KY, USA). MicroAmp 
Optical 96-well Reaction Plates, 96-well Fast PCR Plates, MicroAmp Optical Adhesive Film, 
TaqMan Universal PCR Master Mix No AmpErase UNG and TaqMan SNP Genotyping Assays 
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were purchased from Life TechnologiesTM (Foster City, CA, USA). Tris base, 
ethylenediaminetetraacetic acid (EDTA) and all other reagents were purchased from Sigma-
Aldrich (St. Louis, MO, USA). 
2.2.2 Sample Collection 
The characteristics of all of the samples used and studied in the paper were described in a 
previous study on methadone pharmacogenetics (Richards-Waugh et al., 2014). Briefly, the 
cases for this study were derived from fatalities due to methadone occurring from 2003 to 2008 
in the Offices of the Chief Medical Examiner (OCMEs) of West Virginia (WV) and Kentucky 
(KY). Based on the toxicity criteria, 125 Caucasian cases (78 from WV and 47 from KY) related 
to methadone-only fatalities were selected. A control group of 255 cases was obtained from the 
WV OCME, in which toxicology immunoassays were negative for amphetamines, barbiturates, 
benzodiazepines, buprenorphine, cocaine, methadone, propoxyphene, opiates, oxycodone and 
tricyclic antidepressants. Demographic data for the WV cases, along with the number of KY 
cases are outlined in Table 3. 
 Methadone-Only Overdoses Controls 
WV Cases 78 255 
KY Cases* 47 0 
Total Cases 125 255 
Age Ranges (years) 1.75 – 58 2 – 88 
Mean Age 34.07  11.40 45.35  18.70 
Males (%) 58 (74.4%) 194 (76.1%) 
Females (%) 20 (25.6%) 61 (23.9%) 
Table 3: Demographic of Study Groups 
*Age and gender were not available for the KY Cases 
2.2.3 DNA Extraction 
Following the manufacturer’s protocol for dried blood spots, QIAamp DNA Micro 
extraction kits were used for the purification of genomic DNA from blood stain cards prepared 
by the WV and KY OCMEs. Extractions were performed in triplicate in order to increase overall 
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genomic DNA yields; the three DNA solutions were pooled and then concentrated by passage 
over a MiniElute column. Extracted DNA was quantitated by absorbance spectrophotometry on a 
NanoDrop 1000. Samples were diluted to a concentration of 1.78 ng/µL with Tris-EDTA buffer 
to a final volume of 100 µL for use in the SNP genotyping assays. All genomic DNA samples, 
initial extractions and 1.78 ng/µL working solutions, were stored at 4°C.  
2.2.4 SNP Selection 
Eight different SNPs within the CYP2B6 gene were genotyped. Five exonic SNPs, 
rs3211371 (*5, c.1459C>T, R487C), rs3745274 (*9, c.516G>T, Q172H), rs8192709 (*2, 
c.64C>T, R22C), rs12721655 (*8, c.415A>G, K139E) and rs35979566 (*15, c.1172T>A, 
I391N), were selected because they were considered polymorphic in the Caucasian population, 
and known to encode non-synonymous amino acid substitutions (Figure 2). The remaining three 
SNPs, rs2279344 (18273G>A), rs4803419 (15582C>T) and rs8192719 (21563C>T), were 
intronic and had Minor Allele Frequencies (MAFs) of at least 5% (Figure 2). 
Figure 2: Location of Exonic and Intronic SNPs within the CYP2B6 Gene 
Minor allele frequency in parenthesis. 
 
2.2.5 SNP Genotyping  
The following Life TechnologiesTM TaqMan SNP Genotyping kits were used to 
determine CYP2B6 genotypes: (i) C__26823974_30 (rs2279344), (ii) C__30634242_40 
(rs3211371), (iii) C___7817765_60 (rs3745274), (iv) C___7817764_10 (rs4803419), (v) 
C___2818162_20 (rs8192709), (vi) C__22275631_10 (rs8192719), (vii) C__30634236_20 
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(rs12721655) and (viii) C__33845840_20 (rs35979566). Real-time polymerase chain reaction 
(RT-PCR) and allelic discrimination were carried out in a total volume of a 25 µL reaction, 
containing 20 ng of genomic DNA, TaqMan Universal PCR Master Mix No AmpErase UNG 
(1X) and a TaqMan SNP Genotyping Assay (1X). PCR parameters were set for polymerase 
activation at 95°C for 10 min followed by 50 cycles (rs2279344, rs3211371, rs3745274, 
rs4803419 and rs8192709) or 55 cycles (rs8192719) of denaturation at 92°C for 30 s and 
annealing/extension for 90 s at 60°C for each SNP on an ABI7000 Sequence Detection System. 
SNP rs12721655 and rs35979566 were genotyped on an ABI StepOnePlusTM Instrument using 
the RT-PCR parameters of 95°C for 10 min followed by 65 cycles of 92°C for 15 s and 60°C for 
90 s. All SNP genotypes were determined using both the auto and manual allele call options on 
their respective instrument software.  
2.2.6 Statistical Analysis 
Allele frequencies for the control and methadone-only groups were calculated based on 
the allelic calls for all SNPs in each group. A χ2 test with two degrees of freedom was used to 
assess the differences between the MAFs in the control group and the MAFs reported in the 
National Center for Biotechnology Information (NCBI) dbSNP database for the Caucasian 
population and between the control study group and the methadone-only fatality study group. P-
values < 0.05 were considered to statistically significant. We also assessed whether genotypic 
frequencies for each SNP were in Hardy–Weinberg equilibrium (HWE) using a χ2 test with two 
degrees of freedom. When performing the statistical analysis on the blood methadone 
concentrations and [methadone]/[EDDP] ratio, the methadone-only group was further divided 
into two groups. All 125 fatalities due to methadone were used for the analysis of blood 
methadone concentrations, while only the cases obtained from the WV OCME were used for the 
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analysis of [methadone]/[EDDP] ratios (the KY OCME did not determine EDDP concentrations, 
hence the [methadone]/[EDDP] ratio data were not available). The blood methadone 
concentration measurements were conducted by the OCMEs during the toxicological testing, and 
therefore, represent both the (R)- and (S)- methadone concentrations combined. The mean, 
standard deviation, standard error of the mean (SEM) and unpaired t-test with Welch’s correction 
or one-way analysis of variance (ANOVA) with Tukey test correction was used to compare 
blood methadone concentrations (mg/L) between homozygotes for the major allele (ancestral), 
heterozygotes and homozygotes for the minor allele (variant) in WV/KY methadone-only cases. 
The same tests were also performed to compare [methadone]/[EDDP] ratio between ancestral, 
heterozygotes and variant alleles in the WV methadone-only cases. One-way ANOVA analyses 
were performed only on groups that had a minimum number of two cases for each genotype; an 
unpaired t-test with Welch’s correction was performed in all other cases. Statistical analyses 
were carried out using GraphPad Prism 6 software version 6.02. 
2.2.7 VEP of Non-synonymous SNP Variants 
The consequences of the exonic SNPs were predicted using the online Variant Effect 
Predictor (VEP) tool on EnsemlGenomes (http://useast.ensembl.org/Tools/VEP). SIFT and 
PolyPhen scores were obtained by inputting and running the variant identifiers for Human 
(Homo sapiens) on VEP. 
2.3 Results 
Using the data from the allelic discrimination analysis, genotypic and MAFs were 
calculated for the eight SNPs in all groups (Table 4-11). Two SNPs, rs12721655 (MAF 0.8%) 
and rs35979566 (MAF 0.8%), were not included in the comparison between blood methadone 
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concentration and [methadone]/[EDDP] ratio because the variant allele was not observed in the 
methadone-only group.  
rs2279344 (MAF = 
39.4%)* 
Controls Methadone-Only 
Overdoses (All) 
WV Methadone-
Only Overdoses 
(Male) 
WV Methadone-
Only Overdoses 
(Female) 
Calculated MAF 37.5% 38.4% 39.3% 25.0% 
Homozygous Major 
Allele 
    
Expected 92.9 47.2 21.8 7.8 
Observed 98 45 18 11 
Heterozygotes     
Expected 120.8 56.7 26.3 9.4 
Observed 120 59 32 8 
Homozygous Minor 
Allele 
    
Expected 39.3 17.1 7.9 2.8 
Observed 35 17 6 1 
HWE     
2 3.2E-02 0.11 2.19 8.9E-02 
P-value 0.98 0.95 0.33 0.96 
Obs vs. Exp P-
value 
0.69 0.91 0.30 0.26 
Table 4: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for 
rs227344 
* The expected NCBI MAF is in parentheses beside the db SNP id. 
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rs3211371 (MAF = 
10.4%)* 
Controls Methadone-Only 
Overdoses 
WV Methadone-
Only Overdoses 
(Male) 
WV Methadone-
Only Overdoses 
(Female) 
Calculated MAF 10.3% 12.4% 13.8% 5.0% 
Homozygous Major 
Allele 
    
Expected 203.1 100.6 46.7 16.1 
Observed 205 97 43 18 
Heterozygotes     
Expected 47.2 23.1 10.7 3.7 
Observed 44 25 14 2 
Homozygous Minor 
Allele 
    
Expected 2.7 1.3 0.6 0.2 
Observed 4 3 1 0 
HWE     
2 0.82 0.79 1.3E-02 5.5E-02 
P-value 0.66 0.67 0.99 0.97 
Obs vs. Exp P-
value 
0.67 0.30 0.46 0.55 
Table 5: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for 
rs3211371 
* The expected NCBI MAF is in parentheses beside the db SNP id. 
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rs3745274 (MAF = 
27%)* 
Controls Methadone-Only 
Overdoses 
WV Methadone-
Only Overdoses 
(Male) 
WV Methadone-
Only Overdoses 
(Female) 
Calculated MAF 22.4% 31.9% 35.1% 37.5% 
Homozygous Major 
Allele 
    
Expected 133.2 74.7 34.3 12.0 
Observed 156 58 25 6 
Heterozygotes     
Expected 98.6 43.1 19.8 7.0 
Observed 76 53 24 13 
Homozygous Minor 
Allele 
    
Expected 18.2 6.2 2.9 1.0 
Observed 18 13 8 1 
HWE     
2 3.94 3.0E -02 0.33 3.0 
P-value 0.14 0.99 0.85 0.22 
Obs vs. Exp P-
value 
1.1E-02† 1.2E-03¶ 1.8E-03¶ 1.6E-02‖ 
Table 6: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for 
rs3745274 
* The expected NCBI MAF is in parentheses beside the db SNP id. 
Statistically significant in allele frequency as compared to the NCBI Caucasian population. †P < 
0.01. 
Statistically significant in allele frequency as compared to the control group, ‖P < 0.05, ¶P < 
0.005. 
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rs4803419 (MAF = 
25.1%)* 
Controls Methadone-Only 
Overdoses 
WV Methadone-
Only Overdoses 
(Male) 
WV Methadone-
Only Overdoses 
(Female) 
Calculated MAF 31.1% 24.6% 25.0% 28.9% 
Homozygous Major 
Allele 
    
Expected 142.5 57.9 27.5 9.0 
Observed 126 67 31 8 
Heterozygotes     
Expected 95.5 52.3 24.9 8.1 
Observed 98 50 25 11 
Homozygous Minor 
Allele 
    
Expected 16.0 11.8 5.6 1.8 
Observed 30 5 2 0 
HWE     
2 2.53 1.35 1.30 3.15 
P-value 0.28 0.51 0.52 0.21 
Obs vs. Exp P-
value 
8.2E-04‡ 6.6E -02 0.25 0.23 
Table 7: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for 
rs4803419 
* The expected NCBI MAF is in parentheses beside the db SNP id.  
Statistically significant in allele frequency as compared to the NCBI Caucasian population. ‡P < 
0.001.  
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rs8192709 (MAF = 
3.6%)* 
Controls Methadone-Only 
Overdoses 
WV Methadone-
Only Overdoses 
(Male) 
WV Methadone-
Only Overdoses 
(Female) 
Calculated MAF 5.4% 2.8% 0.9% 2.5% 
Homozygous Major 
Allele 
    
Expected 233.3 111.9 51.9 17.9 
Observed 227 118 57 19 
Heterozygotes     
Expected 17.4 12.7 5.9 2.0 
Observed 21 7 1 1 
Homozygous Minor 
Allele 
    
Expected 0.3 0.4 0.2 0.1 
Observed 3 0 0 0 
HWE     
2 7.95 0.10 4.4E-03 1.3E-02 
P-value 1.9E-02§ 0.95 1.00 0.99 
Obs vs. Exp P-
value 
1.1E-05‡ 0.20 9.3E -02 0.72 
Table 8: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for 
rs8192709 
* The expected NCBI MAF is in parentheses beside the db SNP id. 
Statistically significant in allele frequency as compared to the NCBI Caucasian population. ‡P < 
0.001.  
§ Allele is out of Hardy-Weinberg Equilibrium, P < 0.05. 
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rs8192719 (MAF = 
27.9%)* 
Controls Methadone-Only 
Overdoses 
WV Methadone-
Only Overdoses 
(Male) 
WV Methadone-
Only Overdoses 
(Female) 
Calculated MAF 23.0% 33.6% 35.8% 39.5% 
Homozygous Major 
Allele 
    
Expected 121.1 63.5 31.5 11.3 
Observed 144 48 23 6 
Heterozygotes     
Expected 93.7 37.9 18.8 6.7 
Observed 71 46 22 11 
Homozygous Minor 
Allele 
    
Expected 18.1 5.6 2.8 1.0 
Observed 18 13 8 2 
HWE     
2 4.48 0.15 0.50 0.85 
P-value 0.11 0.93 0.77 0.65 
Obs vs. Exp P-
value 
7.3E-03† 5.2E-04 1.9E-03
¶ 4.5E-02‖ 
Table 9: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for 
rs8192719 
* The expected NCBI MAF is in parentheses beside the db SNP id. 
Statistically significant in allele frequency as compared to the NCBI Caucasian population. †P < 
0.01. 
Statistically significant in allele frequency as compared to the control group, ‖ P < 0.05, ¶ P < 
0.005,  P < 0.001.  
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rs12721655 (MAF = 
0.8%)* 
Controls Methadone-Only 
Overdoses 
WV Methadone-
Only Overdoses 
(Male) 
WV Methadone-
Only Overdoses 
(Female) 
Calculated MAF 0.2% 0.0% 0.0% 0.0% 
Homozygous Major 
Allele 
    
Expected 211.6 100.5 47.8 17.9 
Observed 214 101 48 18 
Heterozygotes     
Expected 3.4 0.5 0.2 0.1 
Observed 1 0 0 0 
Homozygous Minor 
Allele 
    
Expected 0 0 0 0 
Observed 0 0 0 0 
HWE     
2 1.2E-03 ND ND ND 
P-value 1.00 ND ND ND 
Obs vs. Exp P-
value 
0.42 0.79 0.89 0.96 
Table 10: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for 
rs12721655 
* The expected NCBI MAF is in parentheses beside the db SNP id. 
ND:  minor allele was not detected. 
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rs35979566 (MAF = 
0.8%)* 
Controls Methadone-Only 
Overdoses 
WV Methadone-
Only Overdoses 
(Male) 
WV Methadone-
Only Overdoses 
(Female) 
Calculated MAF 1.3% 0.0% 0.0% 0.0% 
Homozygous Major 
Allele 
    
Expected 192.9 90.6 56.5 16.6 
Observed 191 93 58 17 
Heterozygotes     
Expected 3.1 2.3 1.5 0.4 
Observed 5 0 0 0 
Homozygous Minor 
Allele 
    
Expected 0 0 0 0 
Observed 0 0 0 0 
HWE     
2 0.03 ND ND ND 
P-value 0.98 ND ND ND 
Obs vs. Exp P-
value 
0.55 0.30 0.47 0.80 
Table 11: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for 
rs35979566 
* The expected NCBI MAF is in parentheses beside the db SNP id. 
ND:  minor allele was not detected. 
2.3.1 HWE Analysis 
Genotype frequencies within a group were considered to be in HWE if the resulting χ2 
value was < 5.99 (corresponding to a P-value > 0.05). SNP rs8192709 in the control group was 
out of HWE. The remaining five SNPs were in HWE for the control group. The methadone-only 
group was within HWE for all six SNPs. 
2.3.2 Comparison of Observed and Expected Genotypic Frequencies 
To assess for significant differences between the genotypic frequencies in the control 
groups and the NCBI frequencies for the Caucasian population, a χ2 test with two degrees of 
freedom was used. We observed that the genotypic frequency of four SNPs (rs3745274, 
rs4803419, rs8192709 and rs8192719) was significantly different between our control group and 
that of the frequency in the NCBI population. SNPs rs3745274 and rs8192719 in the control 
44 
group had lower than expected MAFs compared to NCBI reported values, 22.4% vs 27.0% and 
23.0% vs 27.9%, respectively, while SNPs rs4803419 and rs8192709 observed higher MAFs, 
31.1% vs 25.1% and 5.4% vs 3.6%, respectively. 
Since many of the control group SNP frequencies were discordant with the NCBI 
frequencies, we relied on genotype frequencies of the local control group to identify SNPs that 
could contribute to methadone toxicity. SNPs rs3745274 and rs8192719 exhibited a significant 
difference in the methadone-only group compared to the control group. For these two SNPs, the 
MAF in the methadone-only cases was greater than that of the control group, 31.9% vs 22.4% 
and 33.6% vs 23.0%, respectively. When assessing the observed and expected genotypic 
frequencies for the male and female groups, the differences in frequencies were preserved in the 
both groups. These results are delineated in Table 4. 
2.3.3 Analysis of Blood Methadone Concentrations and [Methadone]/[EDDP] Ratios  
We tested for associations between SNP genotypes and blood methadone concentrations 
using a one-way ANOVA, in conjunction with the Tukey test. For SNP rs3211371, these 
analyzes showed a significant increase in the mean blood methadone concentrations (mg/L) in 
participants carrying two copies of the variant allele (1.67 ± 0.85) as compared to either the 
heterozygote (0.52 ± 0.08) or homozygous ancestral genotype (0.59 ± 0.05). Figure 3 depicts the 
mean blood methadone concentrations, with SEM, of each of the genotypes for the SNPs tested. 
The metabolic ratio of [methadone]/[EDDP] was significantly lower in heterozygotes carrying 
the rs8192709 variant vs the homozygous ancestral genotype (Figure 4). No significant 
differences in ratios were observed for the remaining SNPs. 
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Figure 3: Comparison for Various CYP2B6 SNPs with SEM of Mean Blood Methadone 
Concentrations 
* Statistically significant difference, P < 0.01. 
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Figure 4: Comparison for Various CYP2B6 SNPs with SEM of Mean [Methadone]/[EDDP] 
Ratios 
* Statistically significant difference, P < 0.05. 
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2.3.4 Predicted Effects of SNPs on Protein Function  
Amino acid substitution (AAS) at the corresponding positions for each of the SNPs were 
predicted for their effect on protein function. VEP reports the possible impact of the SNPs using 
the SIFT and PolyPhen algorithms. Both algorithms were consistent for rs3211371 and 
rs3745274, indicating that the AASs were tolerated and benign, while rs12721655 was predicted 
to affect the protein function in a deleterious and possibly damaging manner. Conflicting results 
were observed for rs8192709 and rs35979566, where the SIFT algorithm predicted the AASs to 
have a deleterious effect on the protein function, while PolyPhen predicted the substitutions to be 
benign. 
2.4 Discussion 
After oral administration, methadone can be detected in the blood within 15 – 45 min, 
and peak plasma concentrations can be attained at 2.5 – 4 h. The bioavailability of methadone is 
~75%, with a wide range of 36 – 100% (Eap et al., 2002; Lugo et al., 2005; Kapur et al., 2011). 
About 86% of methadone binds to α1-acid glycoprotein (AGP), leaving 14% as free plasma 
methadone levels (Kapur et al., 2011). The methadone levels in the plasma decrease as the liver 
enzymes, CYPs, start to metabolize methadone to the inactive metabolites EDDP and EMDP. 
The elimination half-life of methadone ranges from 5 – 130 h, with a mean value of 22 h (Eap et 
al., 2002). The pharmacokinetics of methadone encompasses extreme interindividual variability 
attributed to factors such as, age, co-administered medications, disease, ethnicity (due to 
differing allelic frequency of genetic polymorphisms), gender and weight (Li et al., 2008; Kapur 
et al., 2011; Richards-Waugh et al., 2014). In a previous study, Richards-Waugh et al. (2014) 
demonstrated that an increasing number of SNPs present in CYP3A4 was associated with an 
increasing blood level of methadone. 
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Due to the number of factors contributing to the pharmacokinetics of methadone, this 
study examined CYP2B6 SNPs in 125 Caucasian individuals who suffered methadone-only 
fatalities. Our study eliminated the factors of co-medication and limited it to the allelic frequency 
of the Caucasian population in WV and KY. The methadone-only group was a non-random 
selection of individuals, chosen for the study based on a particular phenotype (fatalities due to 
methadone) of interest in the WV and KY region. In order to accurately determine any 
differences in the genotypic frequencies of the SNPs, the methadone-only group was compared 
to the regional control group. SNPs rs12721655 and rs35979566 did not exhibit any of the 
variant alleles in the methadone group or the control group. This observed genotypic frequency 
could be accredited to the low MAF of 0.8%. The study cohort may not have been large enough 
to reasonably observe the variant allele. The remaining alleles genotyped had a MAF of at least 
2% as reported by the NCBI database. A significant enrichment of the minor alleles of 
rs3745274 and rs8192719 was observed in the methadone-only group compared to the control 
group, (32.2% vs 22.4% and 33.6% vs 23.0%), for the SNPs, respectively. The data suggests that 
these SNP may play a causative role in methadone fatalities. This finding is consistent with the 
observation that rs3745274 and rs8192719 are under-represented in a group of individuals with 
low (S)-methadone levels (Dobrinas et al., 2013) and suggesting their involvement with 
decreased CYP2B6 activity. The significant increase in the number of minor alleles was 
preserved in both the male and female cases, indicating that a particular gender does not have a 
predisposition to the mutation. 
It is unclear if the enrichment of the minor alleles rs3745274 and rs8192719 leads to an 
enhancement of the blood level of (S)-methadone in this study, as enantiomer levels of (R)- and 
(S)-methadone were not determined at the time of autopsy. While total methadone blood levels 
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were not increased by the presence of these SNPs (Figure 3), the ratio of (R)- to (S)-methadone 
is unknown. If the ratio of (S)-methadone was increased due to these SNPs, then it is possible 
that an increased risk of death from cardiotoxicity would exist. 
Parent-to-metabolite ratios are commonly used as an indicator of a recent intake of 
certain drugs and are not necessarily indicative of an acute poisoning. In some cases, the 
metabolic ratio may provide clues to indicate reduced metabolism of the drug due to a drug 
interaction or low metabolic capacity caused by genetics (Druid, Holmgren, Carlsson, & Ahlner, 
1999). It was interesting to see a significant decrease (P = 0.04) in the metabolic ratio in 
individuals that were heterozygous for rs8192709. These data suggest that rs8192709 may have a 
role in metabolizing methadone at a faster rate. This analysis, however, should be interpreted 
with caution, as the number of individuals having a variant was minimal (n = 2), and neither 
were observed to be homozygous for the variant. A significant increase in the blood methadone 
concentration was observed for rs3211371 of homozygous variant alleles when compared to the 
ancestral alleles and the heterozygous genotypes (P = 0.002). This finding suggests that 
rs3211371 results in the reduced activity of CYP2B6. This finding is contrary to the findings of 
Dobrinas et al. (2013). In their study, rs3211371 was over-represented in low-level (S)-
methadone groups, indicating an increased CYP2B6 activity. This study interprets the findings 
based on the various genotypes, whereas Dobrinas et al. (2013) interprets their findings on 
MAFs, which may be the reason of the contradictory postulations. Also, Dobrinas et al. (2013) 
measured enantiomeric levels of methadone in live MMT patients, while our results are from 
autopsy samples. It is also possible that the small sample size of the studies has resulted in these 
differences. Additional numbers of cases could be needed to resolve this difference in findings. 
A combination of the total number of variant alleles present for all of the SNPs tested for each 
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individual in the methadone-only group was determined. The blood methadone concentration 
and the [methadone]/[EDDP] ratio was compared to total number of minor alleles present, 
ranging from one to five copies of the variant alleles for CYP2B6. The data (not shown) did not 
support the assumption that multiple SNPs, rather than a single SNP, on the CYP2B6 gene would 
increase the unexpected fatality from methadone. 
SNP rs3211371 results in a conversion of arginine to cysteine at amino acid position 487, 
while glutamine is converted to histidine at amino acid position 172 as a result of rs3745274. 
Tools for annotating functional predictions of coding non-synonymous SNPs, such as SIFT and 
PolyPhen, suggested that both of these SNPs are tolerated or benign. On the other hand, 
rs8192709 encodes a conversion of arginine to cysteine at amino acid position 22, producing 
disagreeing predictions, where SIFT reports the variation to be deleterious, while PolyPhen 
predicts the mutation to be benign. CYP2B6 has six substrate recognition sites (SRSs) along its 
sequence (Nguyen et al., 2008). SNPs rs3211371, rs3745274 and rs8192709 are not located 
within the known SRSs and confer minimal effects on methadone binding; however the SNPs 
may affect the hydrophobicity and conformation of the protein, resulting in alteration of the 
metabolic rate (Kamal, Lim, Tye, Ismail, & Choong, 2013). Furthermore, rs3745274 has been 
associated with increased levels of a hepatic splicing variant lacking exon 4 – 6 and decreased 
protein levels, caused by erroneous splicing, leading to decreased metabolism of substrates 
(Desta et al., 2007; Hofmann et al., 2008). 
Physiologic differences occur between genders, which may affect the outcome of drug 
activity (Whitley & Linsdey, 2009). Gender influences the expression of CYPs and transporters, 
thus influencing pharmacokinetic parameters (Zanger & Schwab, 2013). Methadone accesses 
MOR site through the bloodstream, coming in contact with the plasma protein AGP. AGP is 
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capable of binding methadone and rendering it inactive (Behan, Cruickshank, Matthews-Smith, 
Bruce, & Smith, 2013). In general, females have a significantly greater binding capacity of AGP 
than males, suggesting that females could have a reduced level of free plasma drug levels 
(Kishino et al., 2002). In this study, there were no significant differences in the blood methadone 
concentration or the [methadone]/[EDDP] ratio between the male and female groups for any of 
the SNPs tested (data not shown). 
It is important to note that since these cases were obtained from the WV and KY 
OCMEs, the medical and prescription history of the deceased individuals was not available. It is 
possible that drugs, prescription or natural supplements, or environmental compounds not 
detected by the normal toxicology screens could also have contributed to altered methadone 
metabolism. Additionally, it is unclear if the ratio of (R)- to (S)-methadone was changed in 
association with any CYP2B6 SNPs examined. Research is currently underway to determine the 
effects of the exonic SNPs included in this study on the differential metabolism of (R)- and (S)-
methadone. 
2.5 Conclusions 
The frequencies of two SNPs on the CYP2B6 gene, rs3745274 (*9, c.516G>T, Q172H) 
and rs8192719 (21563C>T) were significantly increased in the methadone-only group. SNP 
rs3211371 (*5, c.1459C>T, R487C) exhibited a significant increase in the blood methadone 
concentration in the homozygous variant genotype, indicating that an individual carrying two 
copies of the minor allele for the SNP could have a poor methadone-metabolizer phenotype 
leading to an increased risk of fatal methadone intoxication. CYP2B6 only plays a partial role in 
the metabolism of (S)-methadone, and therefore the SNPs on this gene are only a part of the 
whole story. Richards-Waugh et al. (2014) studied the effects of SNPs on the CYP3A4 gene, 
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which metabolizes both the (R)- and (S)- forms of methadone. It is possible that it is a 
combination of SNPs on both genes that leads to these unexpected fatalities. 
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CHAPTER 3 
EFFECTS OF CYTOCHROME P450 2B6 (CYP2B6) SINGLE NUCLEOTIDE 
POLYMORPHISMS ON CYP2B6 ACTIVITY: IMPLICATIONS FOR METHADONE 
METABOLISM 
 
Abstract 
Cytochrome P450 2B6 (CYP2B6) enzyme plays a significant role in the preferential 
stereoselective metabolism of (S)-methadone. Concentrations of (S)-methadone above 
therapeutic levels have the ability to cause serious, life-threatening, and fatal cardiac side effects. 
This toxicity could be due in part to the pharmacogenetics of an individual, which can alter the 
pharmacokinetic and pharmacodynamic properties of the drug and contributing to methadone 
overdose and death. One of the contributing factors for interindividual variability in 
biotransformation is genetic variation within the genes encoding CYP enzymes. Single 
nucleotide polymorphisms (SNPs), located within the CYP2B6 gene were previously genotyped 
in 125 Caucasians involved in methadone-only overdose deaths to determine if these SNPs have 
the potential to play an important role in altering CYP2B6 activity. SNP mutations for 
rs2279344, rs3211371, rs3745274, rs8192709, rs12721655, rs35773040, and rs35979566 were 
introduced to wild type CYP2B6 plasmid using Agilent QuikChange II Site-Directed 
Mutagenesis Kit. Sanger sequencing was performed for all genes to ensure each mutation was 
present. Each of the CYP2B6 plasmids were individually expressed in COS-1 cell lines and the 
transfected cell lines were selectively grown. CYP2B6 microsomal protein was isolated from the 
COS-1 cells. The CYP2B6 activity in microsomal fractions was measured using a Promega 
P450-Glo CYP2B6 Assay Kit. Inhibition studies were conducted using clopidogrel to determine 
that the activity observed was from CYP2B6. Methadone was used to evaluate competition with 
luciferin-2B6 substrate at the active site. The effect of each individual SNP variant resulted in the 
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following decreasing order of CYP2B6 activity: rs2279343 > rs3745274 > wild type 
(CYP2B6*1), rs3211371 > rs8192709 > rs35773040, rs35979566. Relative to the wild type 
CYP2B6, SNPs rs8192709, rs35773040 and rs35979566 yielded 57%, 81%, and 94% decreased 
activity, respectively. The inhibition study with methadone indicated that the binding site is the 
same as luciferin-2B6 substrate. Therefore, our investigations suggest that rs8192709, 
rs35773040, and rs35979566 result in poor metabolizing phenotypes which may be contributing 
factors in decreased metabolism of (S)-methadone. 
3.1 Introduction 
The pharmacogenetics of an individual has the ability to alter the pharmacokinetic and 
pharmacodynamics properties of a drug. CYPs are heme-containing enzymes primarily found in 
the smooth endoplasmic reticulum of hepatic cells. These enzymes are responsible for catalyzing 
the oxidative biotransformation of most drugs. The principal determinant of the pharmacokinetic 
properties of xenobiotics is metabolism, thus affecting the resulting pharmacodynamic effects 
(Tanka, 1998; Turpeinen, 2006; Zanger & Schwab, 2013).  
One of the contributing factors for interindividual variability in biotransformation is 
genetic variation within the genes encoding CYP enzymes. SNPs within a CYP gene may alter 
the enzymatic properties of the resulting protein, modify the metabolic response to a drug, and 
ultimately affect the drug’s therapeutic and adverse effects (Ahmad et al., 2018).  
 Methadone has a wide-ranging half-life of elimination from 5 – 130 hours and a 
bioavailability ranging from 36 – 100%, making it a difficult medication to prescribe due to the 
extreme variability in the interindividual pharmacokinetics (Eap et al., 2002). This variation may 
be due to SNPs within the CYP genes responsible for the metabolism of methadone (Li et al., 
2008). In most countries, methadone is administered as a racemic mixture of equal amounts of 
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(R)- and (S)-methadone. The CYP enzymes stereoselectively metabolize methadone, rendering 
distinct enantiomeric pharmacodynamics properties. While analgesic properties are ascribed to 
(R)-methadone, concentrations above therapeutic levels lead to respiratory depression by acting 
on the MOR controlling respiration in the brainstem (Mitchell et al., 2004; Silverman et al., 
2009; van der Schier et al., 2014). Elevated (S)-methadone levels block the voltage-gated 
potassium channel of the hERG gene resulting in potentially fatal cardiotoxicity by prolonging 
the QT interval causing torsades de pointes (Eap et al., 2007; Ansermot et al., 2010; Dobrinas et 
al., 2013). 
CYP2B6 enzyme plays a significant role in the preferential stereoselective metabolism of 
(S)-methadone. CYP2B6 has 74 allelic variants and 38 haplotypes, rendering it one of the most 
polymorphic genes (Fokkema et al., 2011; Ingelman-Sundberg, 2017; Fokkema & den Dunnen, 
2018a). The genetic variants affect catalytic activity, transcriptional regulation, splicing, and 
mRNA and protein expression. Therefore, SNPs in CYP2B6, and possibly other CYPs, could be 
contributing to the incidence of life-threatening and fatal cardiac side effects of (S)-methadone. 
Our laboratory previously genotyped and analyzed numerous CYP2B6 exonic and 
intronic SNP variants in 125 Caucasians involved in methadone-only fatalities (Ahmad et al., 
2017). It was found that the frequencies of two SNPs on the CYP2B6 gene, rs3745274 (*9, 
c.516G>T, Q172H) and rs8192719 (21563C>T), were significantly increased in the methadone-
only group. SNP rs3211371 (*5, c.1459C>T, R487C) exhibited a significant increase in the 
blood methadone concentration, and rs8192709 (*2, c.64C>T, R22C) may have a role in 
metabolizing methadone at a faster rate. The present work examined the effects of seven exonic 
CYP2B6 SNPs, including the exonic SNPs genotyped in the previous study, in the metabolism of 
(S)-methadone. 
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3.2 Material and Methods 
3.2.1 Material 
Plasmid EX-NEG-M02, an empty control vector, was used as minus-P450 control. 
Plasmid EX-Q0553-M02 with the NCBI accession number: NM_000767.4 sequence, which 
cloned the human CYP2B6 gene, was used as a mutagenesis template. All plasmids were 
obtained via GeneCopoeia (Rockville, MD). QuickChange II site-directed mutagenesis kit was 
purchased from Agilent Technologies (Santa Carla, CA). All primers designed to introduce the 
site-directed mutation were obtained from Sigma Life Sciences (The Woodlands, TX). DH5 E. 
coli cells, COS-1 cells, and clopidogrel bisulfate were generous gifts from Dr. Emine Koc, Dr. 
Jung Han Kim, and Dr. Wei Li, respectively (Marshall University, Huntington, WV, USA). 
QIAprep Spin Miniprep and DNeasy® Blood and Tissue kits were purchased from Qiagen 
(Germantown, MD). All microbiological and cell culture reagents were purchased from Fisher 
Scientific (Hampton, NH) and tissue culture plates were obtained from Midsci (Valley Park, 
MO). Pierce BCA protein assay kit was purchased from ThermoFisher Scientific (Waltham, 
MA). CYP2B6 (H-110) and goat anti-rabbit IgG-HRP antibodies were obtained from Santa Cruz 
Biotechnology (Dallas, TX). Phusion® High-Fidelity PCR Kit was purchased from New England 
Biolabs (Ipswich, MA). Microsome Isolation kit was purchased from BioVision (Milpitas, CA). 
Corning® Supersomes™ Human CYP2B6 + Oxidoreductase + b5, and Corning® Gentest™ 
NADPH Regenerating System, Solutions A and B were purchased from Corning (Corning, NY). 
P450-Glo™ CYP2B6 Assay and Screening System and beetle luciferin, potassium sulfate were 
purchased from Promega (Madison, WI). Racemic methadone (6-dimethylamino-4,4-
diphenylheptan-3-one) hydrochloride reference standard was obtained from Sigma-Aldrich (St. 
Louis, MO). 
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3.2.2 CYP2B6 Plasmid Variants 
3.2.2.1 Construction of CYP2B6 Plasmid Variants 
QuickChange II site-directed mutagenesis kit was used to generate various individual 
CYP2B6 constructs from a plasmid carrying the human wild-type CYP2B6 cDNA (CYP2B6*1): 
(i) rs2279343 (CYP2B6*4, c.785A>G, K262R); (ii) rs3211371 (CYP2B6*5, c.1459C>T, 
R487C); (iii) rs3745274 (CYP2B6*9, c.516G>T, Q172H); (iv) rs8192709 (CYP2B6*2, c.64C>T, 
R22C); (v) rs12721655 (CYP2B6*8, c.415A>G, K139E); (vi) rs35773040 (CYP2B6*14, 
c.419G>A, R140Q); and (vii) rs35979566 (CYP2B6*15, c.1172T>A, I391N). Following the 
manufacturer’s conditions, the reactions were prepared in a final volume of 50 L for each 
variant, containing 50 ng wild-type human CYP2B6 plasmid, 125 ng each of the forward and 
reverse variant primer, 5 L reaction buffer (10x), 1 L dNTP mix, and ddH2O. Before the start 
of each cycle, 1 L of PfuUltra HF DNA polymerase was added to each reaction tube. The 
thermal cycling parameters were set for polymerase activation at 95oC for 30 s, followed by 12 
cycles of denaturation at 95oC for 30 s, annealing at 55oC for 1 min, and extension at 68oC for 8 
min. Following the thermal cycling, the reactions were placed on ice for 2 min. The primers 
designed for the plasmid variants are listed in Table 12. 
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Target Forward Primer (5’  3’) Reverse Primer (5’  3’) 
rs2279343 
(CYP2B6*4) 
CAGCGCCCCCAGGGACCTCATC GATGAGGTCCCTGGGGGCGCTG 
rs3211371 
(CYP2B6*5) 
CCCAACATACCAGATCTGCTTCCTGCCCCG CGGGGCAGGAAGCAGATCTGGTATGTTGGG 
rs3745274 
(CYP2B6*9) 
CCACCTTCCTCTTCCATTCCATTACCGCCAAC GTTGGCGGTAATGGAATGGAAGAGGAAGGTGG 
rs8192709 
(CYP2B6*2) 
GCTACTCCTGGTTCAGTGCCACCCTAACACC GGTGTTAGGGTGGCACTGAACCAGGAGTAGC 
rs12721655 
(CYP2B6*8) 
GGATGGGAGAGCGGAGTGTGGAG CTCCACACTCCGCTCTCCCATCC 
rs35773040 
(CYP2B6*14) 
GGATGGGAAAGCAGAGTGTGGAGGAGC GCTCCTCCACACTCTGCTTTCCCATCC 
rs35979566 
(CYP2B6*15) 
GAAGTATTTCTCAACCTGAGCACTGCTCTCC GGAGAGCAGTGCTCAGGTTGAGAAATACTTC 
Sanger 
Sequencing 
Primers 
CAGCCTCCGGACTCTAGC 
CACTATGAGGGACTTCGGGA  
CGTCCTCCTCTTCCTTGCACTCC 
CAAGGACCTCATCGACACCTAC 
TAATACGACTCACTATAGGG 
GATGGAGCAGATGATGTT 
PCR Primers ATAGAAGACACCGGGACCGA* 
CAGCCTCCGGACTCTAGC† 
CAAGGACCTCATCGACACCTAC‡ 
AGCAGTTTTCCCAGTCACGA* 
GATGGAGCAGATGATGTT† 
TAATACGACTCACTATAGGG‡ 
Table 12: Forward and Reverse Primers for Construction of CYP2B6 Plasmid Variants, Sanger Sequencing, and PCR 
Amplification 
* Annealing temperature calculated from www.neb.com/TmCalculator is 65oC 
† Annealing temperature calculated from www.neb.com/TmCalculator is 56oC; 1.5 L of DMSO was added to the PCR reaction 
‡ Annealing temperature calculated from www.neb.com/TmCalculator is 63oC; 1.5 L of DMSO was added to the PCR reaction 
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3.2.2.2 Transformation and Amplification of CYP2B6 Plasmid Variant 
Competent DH5 E. coli cells were incubated on ice for 30 min with 5 ng of the resulting 
PCR variants products. The cells were heat shocked at 42oC for 45 s and then placed back on ice 
to recover for 2 min. The transformed cells were allowed to grow overnight at 37oC on agar 
plates with 1x ampicillin for selection. An isolated colony from the agar plate, for each variant, 
was propagated in NZY+ broth with 1x ampicillin at 37oC overnight with shaking. Transformed 
DH5 E. coli cells were collected for plasmid extraction following the manufacturer’s protocol 
for the QIAprep Spin Miniprep Kit. The purified plasmids were quantitated by absorbance 
spectrophotometry on a NanoDrop 1000. The CYP2B6 variant plasmids were then given to the 
Marshall University Genomics Core Facility to conduct Sanger sequencing to verify the variants 
were present. Two forward primers and a reverse primer were used for sequencing all plasmids 
(listed in Table 12).  
3.2.3 Transfection of COS-1 Cells 
 COS-1 cells were used for stable expression of the CYP2B6 plasmid variants. For each 
individual variant, three wells in a 6-well tissue culture plate were seeded with 100,000 COS-1 
cells in DMEM + 10% FBS. A lipid-DNA complex was formed using 300 ng of plasmid and 3 
L of Lipofectamine 2000 diluted to 200 L with DMEM. The cells were washed with cold PBS 
and 800 L of DMEM + 10% FBS was added to each plate along with 200 L of their respective 
lipid-DNA complex (variant plasmid complexes for CYP2B6 expression or an empty control 
vector for negative control). The cells were grown in a humidified incubator at 37oC with 5% 
CO2. The media was changed after 24 h to selective media (DMEM + 10% FBS + 1% P/S + 
1mg/mL Geneticin) and incubated for an additional 24 h. The cells were recovered 48 h post-
transfection from the three wells and diluted to one cell per well into 96-well tissue culture plates 
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to construct single clones. The remaining cells where stored under cryogenic conditions. Once 
the wells were about 80% confluent, the cells were gradually expanded to 48-well, 24-well, 12-
well, 6-well, 60-mm, and 100-mm tissue culture plates, consecutively. 
3.2.4 Determination of Protein Expression by Western Blot 
The expression of CYP2B6 variant proteins in COS-1 single clone cell lines were 
assessed using Western blot analysis. Protein was extracted from cells grown to 80-90% 
confluency in a 60-mm tissue culture plate using 100 L RIPA buffer with 1x protease inhibitor. 
The protein concentration for each sample was determined using the Pierce BCA protein assay 
kit, following the manufacturer’s protocol. An aliquot of 10 g of protein of each sample was 
denatured by boiling for 5 min. The proteins were separated on a 10% polyacrylamide gel for 1 h 
at 130V. The gel was then transferred to a nitrocellulose membrane for 1 h at 0.35A. The 
successful transfer and protein loading was verified using Ponceau S stain. The membrane was 
then blocked for nonspecific antibody binding using a 5% w/v non-fat milk/TBST solution (10 
mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20; pH 8.0) for 1 h. A rabbit polyclonal CYP2B6 (H-
110) primary antibody (1:1000) was diluted in 5% non-fat milk/TBST and applied on the 
membrane for incubation at 4oC overnight with continual rocking. The membrane was then 
washed three times with TBST for 7 min before the goat anti-rabbit HRP-linked secondary 
antibody (1:5000 dilution in 5% non-fat milk/TBST) was added for 1 h incubation. The 
membrane was again washed with TBST for 7 min, three times. The proteins were detected with 
the application of ECL and exposure to X-ray film. GAPDH was used as a loading control for all 
of the Western blots to confirm equal protein loading. 
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3.2.5 Verification of Plasmid Variant in Protein Expression 
Once protein expression was determined via Western blotting, the CYP2B6 gene was 
again sequenced to verify the protein was expressing the SNP variant. Each cell line was grown 
to 80-90% confluency in a 100-mm tissue culture plate. The DNA was purified from the cells 
following the manufacturer’s protocol for the DNeasy® Blood and Tissue Kit. The extracted 
DNA was quantitated using the NanoDrop 1000. Phusion® High-Fidelity PCR Kit was used to 
amplify the CYP2B6 gene in a PCR reaction. Following the manufacturer’s conditions, the 
reactions were prepared in a final volume of 50 L for each sample containing 150 ng of the 
purified template DNA, 10 L of 5x Phusion HF, 2.5 L each of 10 M forward and reverse 
primer, 1 L of 10 mM dNTPs, nuclease-free water to volume, and lastly 0.25 L Phusion DNA 
polymerase. The thermocycling conditions were set on three stages: stage one for initial 
denaturation at 98oC for 30 s, followed by stage two for 30 cycles of denaturation at 98oC for 10 
s, annealing at 51o, 56o, or 65oC for 30 s, and extension at 72oC for 26 s, and stage three for a 
final extension at 72oC for 5 min. Following the cycling conditions, the samples were held at 
4oC. The primers designed for the PCR are listed in Table 12. 
Positive PCR amplification was determined through Southern blot analysis on the PCR 
products using a 1% agarose gel with ethidium bromide at a final concentration of 0.5 g/mL. 
The PCR products were then given to the Marshall University Genomics Core Facility to 
conduct Sanger sequencing to verify the variants were present. The sequencing primers used are 
listed in Table 12. DNA BASER Sequence Assembler v.4.36.0 was used to align the sequence 
reads to a reference sequence to form a single continuous contig for each sample. The resulting 
contig was subsequently aligned to the reference plasmid sequence using the multiple sequence 
alignment by CLUSTALW (https://www.genome.jp/tools-bin/clustalw). 
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3.2.6 Isolation and Quantitation of Microsomal Protein 
After the confirmation of the presence of the CYP2B6 SNP variants in the stable 
constructs of COS-1 cells, twenty 100-mm tissue culture plates of each cell line were grown to 
yield approximately 2 x 107 cells. The cells were collected for isolation of microsomal fractions 
by differential centrifugation following the manufacturer’s protocol for BioVision’s Microsome 
Isolation Kit. In short, all steps were performed on ice. The cells were homogenized via 
sonication and then centrifuged at 10,000 x g for 15 min at 4oC. The supernatant was then 
centrifuged at 25,000 x g for 20 min at 4oC. The resulting pellet was resuspended in storage 
buffer and stored at -80oC. The protein concentration for each microsomal extraction was 
determined using the Pierce BCA protein assay kit. An aliquot of 20 g of microsomal protein 
for each sample was used for Western blot analysis as previously described. For each gel, 0.05, 
0.1, 0.15, and 0.2 pmol of Corning® SupersomeTM Human CYP2B6 was loaded as standards to 
produce a standard curve. Densitometry was measured with ImageJ PC-based software (National 
Institute of Health) to extrapolate the concentration of CYP2B6 in each COS-1 microsomal 
extract from the standard curve. 
3.2.7 P450-GloTM Assay 
3.2.7.1 Measuring CYP2B6 SNP activity 
The P450-GloTM CYP2B6 assay was performed in accordance to the manufacturer’s 
protocol in white opaque polystyrene nontreated flat-bottom 96-well plates. In short, 0.1 pmol of 
each CYP2B6 SNP variant microsomal protein were incubated with 25 L of 2X substrate 
solution (final concentration of 3 M luciferin-2B6) for 10 min at 37oC. CYP2B6 reactions were 
initiated with the addition of 25 L 2X NADPH regeneration system and incubated for an 
additional 10 min at 37oC. An addition of 50 L detection reagent was added to cease the 
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reaction and shaken on an orbital shaker at a frequency of 282 rpm for 10 s and incubated for 20 
min at room temperature in the dark. Luminescence signals were measured using a Synergy 
HTX multi-mode microplate reader. The CYP2B6 activity was normalized to activity detected 
for the empty vector microsomal fractions (minus-P450 control). All reactions were performed in 
triplicate. 
3.2.7.2 Inhibition of CYP2B6 activity 
CYP2B6 was selectively inhibited with a final concentration of 0.5 M and 1.0 M 
clopidogrel to ensure the activity observed was from the CYP2B6 enzyme. Similarly, 0.1 pmol 
of CYP2B6*1 microsomal protein was incubated with 12.5 L of 4X substrate solution (final 
concentration of 3 M luciferin-2B6) and 12.5 L of the appropriate clopidogrel stock solution 
for 10 min at 37oC. The reaction was initiated with the addition of 25 L 2X NADPH 
regeneration system and incubated for an additional 10 min at 37oC. The reaction was terminated 
and luminescent signal was initiated with the addition of 50 L detection reagent. The plate was 
shaken on an orbital shaker at a frequency of 282 rpm for 10 s and incubated for 20 min at room 
temperature in the dark. Luminescence signals were measured on a microplate reader as above. 
The CYP2B6 activity was normalized to activity detected for the untreated control at each 
incubation time point. All reactions were performed in triplicate. 
Various concentrations of racemic methadone (3, 6, 12, 60, 120, and 240 M) was also 
used to test for inhibition. The reactions were carried out and luminescence signals were 
measured and normalized in the same manner as the inhibition with clopidogrel. All reactions 
were performed in triplicate. 
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3.2.8 Statistical Analysis 
Statistical analyses were carried out using GraphPad Prism software version 7.02. The 
CYP2B6 SNP activity was compared to wild type CYP2B6 activity using one-way ANOVA 
with Dunnett’s multiple comparison test. P-values < 0.05 were considered to be statistically 
significant. 
3.3 Results and Discussion 
In order to test the effects of missense variants on human CYP2B6 enzymatic activity, we 
created a wild type CYP2B6 expression vector in plasmid EX-Q0553-M02 and a series of 
variant CYP2B6 expression vectors. We then expressed the resulting enzymes by stable 
transfection in COS-1 cells.  The COS-1 cell line was selected because CYPs are not innately 
expressed by these cells. COS-1 cells also have ample oxidoreductase and cytochrome b5 to 
support the CYP2B6 activity (Gonzalez & Korzekwa, 1995). The variant constructs included the 
following missense substitutions: (1) rs2279343 (CYP2B6*4, c.785A>G, K262R), (2) rs3211371 
(CYP2B6*5, c.1459C>T, R487C), (3) rs3745274 (CYP2B6*9, c.516G>T, Q172H), (4) 
rs8192709 (CYP2B6*2, c.64C>T, R22C), (5) rs12721655 (CYP2B6*8, c.415A>G, K139E), (6) 
rs35773040 (CYP2B6*14, c.419G>A, R140Q), and (7) rs35979566 (CYP2B6*15, c.1172T>A, 
I391N) (Appendix B).  We successfully transfected the wild type construct and all variant 
construct with the exception of the SNP rs12721655 variant plasmid. This observation may stem 
from lethal effects of the variant enzyme and is consistent to the predicted SIFT and PolyPhen 
algorithms of rs12721655 having a deleterious and possibly damaging protein function (Ahmad 
et al., 2017). As a result, no further studies were conducted on the SNP. 
Expression of the wild type and variant proteins was confirmed by Western blot analysis 
on whole cell extracts with CYP2B6 (H-110) antibody (Figure 5); a 55kDa band was not 
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detected in the empty vector transfectant. After verification of protein expression, the presence of 
the CYP2B6 genetic variants in COS-1cells was confirmed by amplification and sequencing of 
the CYP2B6 gene (Appendix B). 
 
Figure 5: Western Blot Analysis of CYP2B6 Variant Protein Expression from Whole Cell 
Lysates 
The activity of the wild type and variant enzymes was measured in COS-1 microsomal 
extracts using the Promega P450-Glo CYP2B6 Assay Kit. In this assay, CYP2B6 enzymes 
metabolized a luminogenic luciferin-2B6 substrate to produce d-luciferin that generates light 
proportional to the CYP2B6 activity. Since SNP rs8192709 produced a lower than expected 
microsomal extract, 0.086pmol of the variant proteins were used to compare SNP activity. The 
activity of the CYP2B6 protein variants was rs2279343 > rs3745274 > wild type (CYP2B6*1), 
rs3211371 > rs8192709 > rs35773040, rs35979566 (Figure 6). Similar results were seen using 
0.1 pmol microsomal protein (data not shown). Compared to the wild type CYP2B6, SNPs 
rs2279343 and rs3745274 resulted in a 90% and 55% increase in CYP2B6 activity, respectively 
(P < 0.0001). In contrast, SNPs rs8192709, rs35773040, and rs35979566 yielded decreased 
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CYP2B6 activity by, 57%, 81%, and 94%, respectively (P < 0.0001). SNP rs3211371 had 
activity comparable to the wild type CYP2B6 enzyme (Figure 6). 
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Figure 6: Effect of CYP2B6 SNPs on CYP2B6 Enzyme Activity. 
Results are the mean with SEM of three P450-Glo reactions. 0.086 pmoles of 2B6 enzyme were 
loaded into assay.  
**** Statistically significant difference with respect to wild type CYP2B6, P < 0.0001. 
 
Clopidogrel is a selective inhibitor of CYP2B6, inactivating the cytochrome activity 
primarily through the destruction of the heme subunit. Clopidogrel is metabolically 
biotransformed to the active metabolite 2-oxo-clopidogrel by CYP2B6. Covalent modification of 
Cys475 of CYP2B6 by 2-oxo-clopidogrel may also lead to the loss of the catalytic activity of 
CYP2B6 (Zhang, Amunugama, Ney, Cooper, & Hollenberg, 2011). Using clopidogrel as an 
inhibition control confirmed that the induced activity observed was from the CYP2B6 enzyme. 
Addition of 0.5 M clopidogrel and 1 M clopidogrel to wild type CYP2B6 microsomal extracts 
resulted in reduction of CYP2B6 activity by 62% and 86%, respectively (P < 0.0001) (Figure 7). 
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The inhibitory concentration at which the CYP2B6 enzyme activity is reduced by 50% (IC50) 
was determined to be 0.393 M using the online source AAT Bioquest IC50 Calculator (Quest 
Graph™ IC50 Calculator, 2018). 
 
0
 
M
 C
l o
p
i d
o
g
r
e
l
0
. 5
 
M
 C
l o
p
i d
o
g
r
e
l
1
 
M
 C
l o
p
i d
o
g
r
e
l
0
2 0 0
4 0 0
6 0 0
8 0 0
R
e
l
a
t
i
v
e
 L
u
m
i
n
e
s
c
e
n
c
e
 U
n
i
t
, 
R
L
U
* * * *
* * * *
 
Figure 7: Wild Type CYP2B6 Enzyme Activity Inhibited by 0.5 M and 1 M of 
Clopidogrel 
Results are the mean with SEM of three reactions. Statistically significant difference compared 
to untreated wild type CYP2B6 enzyme, ****P < 0.0001. 
Racemic methadone was used as a test compound to determine the effect on the wild type 
CYP2B6 enzyme. Inhibition by clopidogrel determined the capacity of the system to detect 
inhibition by racemic methadone. Significant inhibition was not seen at racemic methadone 
concentrations of 3 M, 6 M, and 12 M (data not shown). However, concentrations at 60 M, 
120 M, and 240 M, resulted in an inhibition of the wild type CYP2B6 enzyme with a 
significant decrease in activity by 24%, 34%, and 46%, respectively (P < 0.005, P < 0.0005, and 
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P < 0.0001, respectively) (Figure 8). The IC50 value was calculated to be 304 M of racemic 
methadone, over 100 times the luciferin-2B6 concentration in the assays, indicating methadone is 
a weak competitive inhibitor for the substrate luciferin-2B6. 
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Figure 8: Wild Type CYP2B6 Enzyme Activity Inhibited by 60 M, 120 M, and 240 M 
of Racemic Methadone 
Results are the mean with SEM of three reactions. Statistically significant difference compared 
to untreated wild type CYP2B6 enzyme, **P < 0.005, ***P < 0.0005, ****P < 0.0001. 
SNP rs2279343 (K262R) also resulted in an increase in activity as compared to the wild 
type CYP2B6. In the CYP2B family, variant R262 is involved in a hydrogen-bonding network in 
the G and H helices, along with their associated loops, which includes H252, T255, D263, and 
D266. The ancestral K262 of CYP2B6 disrupts this hydrogen-bonding network, which may 
affect the G and I helices and alter the active site (Gay, Roberts, & Halpert, 2010). SNP 
rs2279343 reverts the lysine in position 262 to the CYP2B conserved arginine residue, which 
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may increase the plasticity of CYP2B6 to adopt different confirmations when binding to 
different substrates, thus resulting in an increase in the observed activity.  
In previous studies, the frequency of the exonic SNP rs3745274 was observed to be 
significantly increased in 125 Caucasian individuals who suffered fatalities due to methadone, in 
the WV and KY regions (Ahmad et al., 2017), indicating SNPs rs3745274 may be linked to 
methadone toxicity overdosing. However, the activity of CYP2B6 SNP rs3745274 (Q172H) 
when compared to the wild type CYP2B6 yielded an increase in CYP2B6 activity (P < 0.0001), 
indicating the SNP results in an ultra-rapid metabolizer phenotype. These results were not in 
agreement to the findings by Gadel et al. (2015), who found that the in vitro intrinsic clearance 
of methadone to its principal metabolite, EDDP, was significantly less in the mutant than the 
wild type CYP2B6 from insect cells co-expressed with oxidoreductase and cytochrome b5. 
Similarly, clinical genetic association studies of concentration-to-dosage ratios and methadone 
plasma concentrations were consistent with diminished methadone N-demethylation in the 
presence of the rs3745274 SNP (Wang et al., 2011; Levran et al., 2013). 
One of the most common CYP2B6 variant alleles is CYP2B6*6, a haplotype harboring 
both the rs2279343 (K262R) and rs3745274 (Q172H) non-synonymous coding SNPs. 
Individually, both of these SNPs increased the activity of CYP2B6 enzymes in our studies. 
Numerous in vitro and clinical studies reported CYP2B6*6 genotype has been linked with an 
increase in methadone plasma levels, decreased methadone N-demethylation, and decreased 
methadone clearance (Gadel et al., 2015; Crettol et al., 2005; Crettol et al., 2006; Kharasch & 
Stubbert, 2013; Kharasch et al., 2015; Kringen et al., 2017). The CYP2B6*6 allele has been 
associated with reduced protein levels, which may be correlated to rs3745274 involved in the 
erroneous hepatic splicing of exons 4, 5 and 6 yielding a truncated protein and concurrently 
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altering the catalytic activity of the enzyme. In silico analysis of the splice sites suggest an 
exonic splicing enhancer may be modulated by rs3745274 in exon 4. These observations were 
from the expression and analysis of minigene constructs created and expressed in COS-1 and 
Huh7 cell lines by Hofmann et al. containing all nine exons of CYP2B6, introns 2, 5, and 7, and 
the 5’ and 3’ parts of introns 3 and 6. The minigenes lacked introns 1, 4, and 8 and parts of intron 
3 and 6 (Hofmann et al., 2008). However, linkage disequilibrium (LD) analysis in an Israeli 
population supported the inclusion of the intronic SNP rs8192719 (intron 8, g.21563C>T) in the 
CYP2B6*6 haplotype (Levran et al., 2013). Although an LD analysis was not performed in our 
previous study, all subjects identified with the rs3745274 SNP also had the rs8192719 SNP 
(unpublished data). It is possible that decreased activity of CYP2B6*6 may be causal from the 
intronic SNP, affecting splice-dependent quantitative and qualitative expression of CYP2B6, 
controlling the efficacy and toxicity of methadone. 
The CYP2B6 activity of SNP rs3211371 was comparable to that of the wild type 
CYP2B6. In comparison to various clinical and decedent studies, these findings were not 
consistent. Individuals homozygous for SNP rs3211371 of methadone-only deceased cohort by 
Ahmad et al. (2017), had a significant increase in blood methadone concentrations, suggesting a 
PM phenotype. In another study, SNP rs3211371 was over-represented in individuals with low 
(S)-methadone levels, indicating an increase in CYP2B6 activity (Dobrinas et al., 2013). While, 
the IV and oral methadone plasma concentrations of SNP rs3211371 homozygote subjects 
resembled those seen in the cohort homozygous for the wild type CYP2B6 (Kharasch et al., 
2015).  
Reduced CYP2B6 activity was observed with SNP rs8192709, causing a non-
synonymous amino acid change in position 22 from a large, positively charged arginine to a 
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medium, nonpolar nucleophilic cysteine. Protein folding may be interfered by cross bridges 
formed by cysteine residues, increasing the rigidity of the protein. SNP rs35773040 causes an 
amino acid change from a positively charged arginine to a polar, uncharged glutamine at position 
140. This mutation is located at the end of the C-D loop (Nguyen et al., 2008), which may 
disrupt interactions with the D helix of CYP2B6, resulting in conformational modifications. 
Replacement of the hydrophobic Ile391 with a less bulky polar uncharged residue (asparagine), 
due to SNP rs35979566, diminished the CYP2B6 activity. This effect may be related to the 
position of this residue directly between the 1-3 sheet and the K’ helix (Nguyen et al., 2008). 
CYP2B6 is only one enzyme involved in the metabolism of (S)-methadone. Cytochromes 
2D6 and 2C18 also preferentially metabolize (S)-methadone, while CYP3A4 demonstrates no 
stereoselectivity, metabolizing both (R)- and (S)-methadone (Ahmad et al., 2018). The 
contradictory results seen in this and other studies with clinical data could be in part due to a 
combination of these CYPs and are not only that of CYP2B6 alone. 
3.4 Conclusions 
In summary, metabolically competent cell systems were generated by stable transfection 
with individual CYP2B6 variant plasmids in COS-1 cells. The effect of introducing one exonic 
SNP resulted in the following decreasing order of CYP2B6 activity: rs2279343 > rs3745274 > 
wild type (CYP2B6*1), rs3211371 > rs8192709 > rs35773040, rs35979566. SNPs rs8192709, 
rs35773040 and rs35979566 yielded 57%, 81%, and 94% decreased activity relative to wild type 
CYP2B6, respectively. Methadone binds to the same active site and competes with the luciferin-
2B6 substrate used to measure CYP2B6 activity. Therefore, our results suggest that these three 
SNPs could contribute to PM phenotypes and may influence the pharmacokinetics and 
pharmacodynamics of (S)-methadone. 
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CHAPTER 4 
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
It is interesting to observe the history and trends of methadone use unfold over the last 20 
years; once a miracle drug, methadone is now a killer cure. In the mid-1990s, methadone was 
increasingly prescribed as a treatment for chronic nonmalignant pain because of its long duration 
of analgesic action and relatively low cost (Paulozzi, Mack, & Jones, 2012). In 2003, West 
Virginia was one of the first states to start reporting increases in fatal overdoses associated with 
methadone (Lipman, 2008). By 2004, the methadone mortality rate in West Virginia increased 
25-fold compared to 1999, while Kentucky showed the fourth largest increase at 15-fold 
(Fingerhut, 2006). The rate of methadone overdoses peaked in 2006, plateaued in 2007, and then 
declined 6.5%, on average, in each subsequent year (Jones et al., 2016; Faul, Bohm, & 
Alexander, 2017). 
The main determinant of methadone mortality rates parallel the amount of methadone 
distributed for pain relief through prescriptions (Paulozzi et al., 2012). In 2006, the FDA issued a 
public health advisory for respiratory depression and cardiac arrhythmias leading to 
unintentional overdose deaths related to methadone used for pain, which was quickly followed 
with issuance of black box warnings by drug manufacturers (Christie, 2011). At the request of 
the Drug Enforcement Agency (DEA), manufacturers voluntarily limited the distribution of the 
40 mg methadone formulation to MMT programs and hospitals at the beginning of 2008, since 
this dosage was not approved for treatment of pain. The steps taken by the FDA and DEA to 
improve the safety of methadone usage may have caused the resulting decline in methadone 
related mortality rate in consistence with the decrease in the national distribution of methadone 
(Paulozzi et al., 2012). However, the overdose death rate in people 55 – 64 years of age 
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continued to rise through 2014 and remains a drug that disproportionately contributes to fatal 
overdoses among opioid pain relievers (Paulozzi et al., 2012; Jones et al., 2016).  
Methadone mortality rate can partially be attributed to the genetic makeup of an 
individual. SNPs in regions of the genome that express drug metabolizing enzymes, CYPs, may 
have consequences that lead to decreased metabolism of methadone leading to unintentional 
overdoses. The CYP2B6 enzyme is one of the predominant metabolizers of methadone, and a 
major determinant of stereoselective metabolism of (S)-methadone (Chang et al., 2011). 
Studying and understanding the pharmacogenetic factors in methadone metabolism can help 
mediate the proper dosing regimen for an individual for safe and effective therapeutic success in 
pain relief. Several pharmacogenetic studies on CYP2B6 have been previously conducted 
involving patients in MMT programs (Crettol et al., 2005; Crettol et al., 2006; Eap et al., 2007; 
Wang et al., 2011; Dobrinas et al., 2013; Kharasch & Stubbert, 2013; Levran et al., 2013; 
Kharasch et al., 2015; Kringen et al., 2017). However, these studies had small sample sizes 
(Kharasch & Stubbert, 2013), included multidrug cases rather than single-drug methadone cases 
(Eap et al., 2007; Wang et al., 2011), or consisted of subject groups of mixed populations  
(Crettol et al., 2005; Crettol et al., 2006; Dobrinas et al., 2013; Levran et al., 2013; Kharasch et 
al., 2015). The work presented in this dissertation is from the largest methadone-only fatalities 
from a single population cohort. It is a unique pharmacogenetic study designed to gain 
knowledge in the prevalence and function of SNPs in CYP2B6.  
The current study was designed to extract the genomic DNA of 125 Caucasian subjects 
from the Appalachian region (WV and KY) involved in methadone-only fatalities from blood 
stain cards, along with a control group consisting of 225 deceased Caucasian individuals from 
WV who screened negative for central nervous system drugs. Eight key exonic and intronic SNP 
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variants present in the Caucasian population were genotyped to test for enrichment in the 
subjects. The analyses performed in this study were aimed to provide insight into the association 
of CYP2B6 SNPs in individuals who succumb to methadone intoxication in the methadone-only 
cases. Many of the control group SNP frequencies were significantly different from the MAF 
reported for the general Caucasian population in the NCBI dbSNP database (Tables 6 – 9). These 
differences indicated that the population in the Appalachia region has evolved, and as such, we 
relied on genotypic frequencies of the local control group to identify SNPs that could contribute 
to methadone toxicity. The frequencies of two SNPs on the CYP2B6 gene, rs3745274 (*9, 
c.516G>T, Q172H) and rs8192719 (21563C>T) were significantly increased in the methadone-
only group compared to the control group (Tables 6 and 9). Associations were also analyzed 
between SNP genotypes and blood methadone concentrations. SNP rs3211371 exhibited a 
significant increase in the blood methadone concentration in the homozygous variant genotype as 
compared to either the heterozygous or homozygous ancestral genotype (Figure 3). This study 
suggested that these three SNPs may be associated as contributory factors to increased 
methadone mortality rates.  
In addition to the pharmacogenetic association study, the effect of each individual exonic 
SNP on the activity of the CYP2B6 enzyme was determined. This current study was conducted 
by generating metabolically competent cell systems by stably transfecting individual CYP2B6 
exonic variant plasmids in COS-1 cell lines. The effect of each exonic SNP on enzyme activity 
was measured using a luminogenic CYP assay and compared to the wild type CYP2B6 enzyme. 
This study showed that the genetic variants of CYP2B6 influences the enzymatic activity in the 
following decreasing order: rs2279343 > rs3745274 > wild type (CYP2B6*1), rs3211371 > 
rs8192709 > rs35773040, rs35979566. SNPs rs8192709, rs35773040, and rs35979566 yielded 
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57%, 81%, and 94% decreased activity relative to wild type CYP2B6, respectively. To further 
explore the effect of these SNPs on the metabolism of methadone, various methadone 
concentrations were added to the assay to competitively inhibit CYP2B6 activity. The data 
indicated that methadone also binds to the CYP2B6 active site and competes with the 
luminogenic substrate used to measure the activity. Therefore, our investigations suggest that 
these three SNPs may contribute to CYP2B6 PM phenotypes and may influence the 
pharmacokinetics and pharmacodynamics of (S)-methadone leading to unanticipated fatalities. 
Since the time of the genotyping study, a TaqMan® SNP Genotyping kit for SNP 
rs35773040 (C__34816082_30) has become available. A custom designed assay for 
rs2279343 (AHBJ12M) can now also be obtained through ThermoFisher Scientific 
(Bloom et al., 2013). These kits should be used to genotype the methadone-only and 
control cases. With this additional information, the CYP2B6*6 haplotype, which is made 
up by SNPs rs2279343 and rs3745274, can be identified in these individuals. Statistical 
analysis, conducted as described in Chapter 2, could reveal more SNPs that may be 
associated with methadone overdoses in the WV and KY populations.  
The purpose of this study was to determine the role of CYP2B6 SNPs in the unexpected 
death due to methadone overdoses. While it has unveiled SNPs enriched in those deceased 
individuals from the heart of the Appalachia region and SNPs that reduce the enzymatic activity 
of CYP2B6, there are several questions left unanswered. The data amongst the association and 
functionality studies are not complimentary. SNP rs3745274 was enhanced in methadone-only 
cases, however the SNP yielded an increase in CYP2B6 activity. Similarly, SNP rs3211371 was 
correlated with a significant increase in the blood methadone concentration, yet the effect of 
CYP2B6 activity was comparable to the wild type. While rs8192709 was associated with an 
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increase in methadone metabolism, the CYP2B6 activity was significantly decreased with the 
presence of this SNP. We determined the effect of individual SNPs on the activity of the 
CYP2B6 enzyme; however, the deceased individuals expressed multiple SNPs in their genetic 
profile for methadone metabolizing CYPs. The combined effect of SNPs on multiple CYPs may 
be the contributory factor to the discrepancies observed between the two studies. In order to 
understand the complexity of the effects of CYP2B6 SNPs on methadone pharmacokinetics and 
pharmacodynamics, further functionality testing should be conducted with combinations of 
SNPs. For example, a plasmid constructed to contain the common haplotype CYP2B6*6, would 
be useful since clinical evidence suggests this genotype influences methadone disposition 
(Crettol et al., 2005; Crettol et al., 2006; Eap et al., 2007; Wang et al., 2011). Any number of 
CYP2B6 SNP combinations would impart a greater understanding in the effects of the SNPs in 
CYP2B6 activity, be it a compound effect with multiple PM SNPs or a null effect with an 
extensive metabolizer SNP in combination with a PM SNP. 
The CYP2B6 enzyme is only involved partially in the metabolism of (S)-methadone, and 
therefore, the SNPs on this gene are only a fraction of the whole story.  Previous studies 
conducted by our laboratory determined the association of SNPs on the CYP3A4 gene, which 
metabolizes both the (R)- and (S)- forms of methadone.  It was found that SNPs rs2242480 and 
rs2740574 were enriched within the methadone-only group (Richards-Waugh et al., 2014). 
Studies on the effect of these CYP3A4 SNPs should be conducted as outlined in Chapter 3. It is 
possible that it is a combination of SNPs on both the CYP2B6 and CYP3A4 genes leads to 
unintentional methadone overdoses. This additional research will help elucidate the role of the 
different CYPs and their polymorphisms in methadone pharmacokinetics and thus the 
therapeutic outcome.  
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APPENDIX B: MULTIPLE SEQUENCE ALIGNMENT OF CYP2B6 SNP PLASMID VARIANTS1 TO NCBI REFERENCE 
SEQUENCE PRE- AND POST-TRANSFECTION2 OF COS-1 CELLS 
 
CYP2B6 Plasmid (NM_000767.4) ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50 
Wild Type (CYP2B6*1)  ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50 
rs2279343 (CYP2B6*4)  ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50 
rs3211371 (CYP2B6*5)  ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50 
 
rs8192709 (CYP2B6*2)  ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50 
rs12721655 (*8, c.415A>G)  ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50 
 
rs35979566 (CYP2B6*15)  ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50 
 
CYP2B6 Plasmid (NM_000767.4) ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100 
Wild Type (CYP2B6*1)  ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100 
rs2279343 (*4, c.785A>G)  ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100 
rs3211371 (*5, c.1459C>T)  ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100 
 
rs8192709 (*2, c.64C>T)  ACTCCTGGTT CAGTGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100 
rs12721655 (*8, c.415A>G)  ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100 
 
rs35979566 (*15, c.1172T>A) ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100 
 
 
 
 
                                                 
1 Single nucleotide polymorphisms (SNPs) are highlighted in turquoise. 
2 Transfection of COS-1 cells with SNP rs12721655 variant plasmid was lethal and resulted in cell death. Therefore, Sanger sequencing on this SNP was 
performed only on the plasmid pre-transfection. 
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CYP2B6 Plasmid (NM_000767.4) CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150 
Wild Type (CYP2B6*1)  CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150 
rs2279343 (*4, c.785A>G)  CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150 
rs3211371 (*5, c.1459C>T)  CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150 
 
rs8192709 (*2, c.64C>T)  CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150 
rs12721655 (*8, c.415A>G)  CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150 
 
rs35979566 (*15, c.1172T>A) CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150 
 
CYP2B6 Plasmid (NM_000767.4) CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200 
Wild Type (CYP2B6*1)  CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200 
rs2279343 (*4, c.785A>G)  CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200 
rs3211371 (*5, c.1459C>T)  CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200 
 
rs8192709 (*2, c.64C>T)  CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200 
rs12721655 (*8, c.415A>G)  CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200 
 
rs35979566 (*15, c.1172T>A) CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200 
 
 
CYP2B6 Plasmid (NM_000767.4) GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250 
Wild Type (CYP2B6*1)  GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250 
rs2279343 (*4, c.785A>G)  GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250 
rs3211371 (*5, c.1459C>T)  GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250 
 
rs8192709 (*2, c.64C>T)  GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250 
rs12721655 (*8, c.415A>G)  GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250 
 
rs35979566 (*15, c.1172T>A) GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250 
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CYP2B6 Plasmid (NM_000767.4) TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300 
Wild Type (CYP2B6*1)  TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300 
rs2279343 (*4, c.785A>G)  TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300 
rs3211371 (*5, c.1459C>T)  TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300 
 
rs8192709 (*2, c.64C>T)  TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300 
rs12721655 (*8, c.415A>G)  TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300 
 
rs35979566 (*15, c.1172T>A) TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300 
 
CYP2B6 Plasmid (NM_000767.4) ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350 
Wild Type (CYP2B6*1)  ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350 
rs2279343 (*4, c.785A>G)  ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350 
rs3211371 (*5, c.1459C>T)  ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350 
 
rs8192709 (*2, c.64C>T)  ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350 
rs12721655 (*8, c.415A>G)  ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350 
 
rs35979566 (*15, c.1172T>A) ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350 
 
CYP2B6 Plasmid (NM_000767.4) TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400 
Wild Type (CYP2B6*1)  TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400 
rs2279343 (*4, c.785A>G)  TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400 
rs3211371 (*5, c.1459C>T)  TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400 
 
rs8192709 (*2, c.64C>T)  TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400 
rs12721655 (*8, c.415A>G)  TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400 
 
rs35979566 (*15, c.1172T>A) TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400 
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CYP2B6 Plasmid (NM_000767.4) ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450 
Wild Type (CYP2B6*1)  ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450  
rs2279343 (*4, c.785A>G)  ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450 
rs3211371 (*5, c.1459C>T)  ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450 
 
rs8192709 (*2, c.64C>T)  ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450 
rs12721655 (*8, c.415A>G)  ACTTCGGGAT GGGAGAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450 
 
rs35979566 (*15, c.1172T>A) ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450 
 
CYP2B6 Plasmid (NM_000767.4) CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500 
Wild Type (CYP2B6*1)  CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500 
rs2279343 (*4, c.785A>G)  CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500 
rs3211371 (*5, c.1459C>T)  CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500 
 
rs8192709 (*2, c.64C>T)  CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500 
rs12721655 (*8, c.415A>G)  CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500 
 
rs35979566 (*15, c.1172T>A) CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500 
 
CYP2B6 Plasmid (NM_000767.4) CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550 
Wild Type (CYP2B6*1)  CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550 
rs2279343 (*4, c.785A>G)  CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550 
rs3211371 (*5, c.1459C>T)  CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550 
 
rs8192709 (*2, c.64C>T)  CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550 
rs12721655 (*8, c.415A>G)  CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550 
 
rs35979566 (*15, c.1172T>A) CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550 
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CYP2B6 Plasmid (NM_000767.4) TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600 
Wild Type (CYP2B6*1)  TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600 
rs2279343 (*4, c.785A>G)  TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600 
rs3211371 (*5, c.1459C>T)  TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600 
 
rs8192709 (*2, c.64C>T)  TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600 
rs12721655 (*8, c.415A>G)  TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600
 
rs35979566 (*15, c.1172T>A) TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600 
 
CYP2B6 Plasmid (NM_000767.4) TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650 
Wild Type (CYP2B6*1)  TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650 
rs2279343 (*4, c.785A>G)  TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650 
rs3211371 (*5, c.1459C>T)  TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650 
 
rs8192709 (*2, c.64C>T)  TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650 
rs12721655 (*8, c.415A>G)  TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650 
 
rs35979566 (*15, c.1172T>A) TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650 
 
CYP2B6 Plasmid (NM_000767.4) TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700 
Wild Type (CYP2B6*1)  TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700 
rs2279343 (*4, c.785A>G)  TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700 
rs3211371 (*5, c.1459C>T)  TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700 
 
rs8192709 (*2, c.64C>T)  TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700 
rs12721655 (*8, c.415A>G)  TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700 
 
rs35979566 (*15, c.1172T>A) TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700 
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CYP2B6 Plasmid (NM_000767.4) TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750 
Wild Type (CYP2B6*1)  TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750 
rs2279343 (*4, c.785A>G)  TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750 
rs3211371 (*5, c.1459C>T)  TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750 
 
rs8192709 (*2, c.64C>T)  TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750 
rs12721655 (*8, c.415A>G)  TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750
 
rs35979566 (*15, c.1172T>A) TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750 
 
CYP2B6 Plasmid (NM_000767.4) AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800 
Wild Type (CYP2B6*1)  AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800 
rs2279343 (*4, c.785A>G)  AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAGGGACC TCATCGACAC 800 
rs3211371 (*5, c.1459C>T)  AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800 
 
rs8192709 (*2, c.64C>T)  AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800 
rs12721655 (*8, c.415A>G)  AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800 
 
rs35979566 (*15, c.1172T>A) AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800 
 
CYP2B6 Plasmid (NM_000767.4) CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850 
Wild Type (CYP2B6*1)  CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850 
rs2279343 (*4, c.785A>G)  CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850 
rs3211371 (*5, c.1459C>T)  CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850 
 
rs8192709 (*2, c.64C>T)  CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850 
rs12721655 (*8, c.415A>G)  CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850 
 
rs35979566 (*15, c.1172T>A) CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850 
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CYP2B6 Plasmid (NM_000767.4) GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900 
Wild Type (CYP2B6*1)  GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900 
rs2279343 (*4, c.785A>G)  GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900 
rs3211371 (*5, c.1459C>T)  GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900 
 
rs8192709 (*2, c.64C>T)  GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900 
rs12721655 (*8, c.415A>G)  GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900 
 
rs35979566 (*15, c.1172T>A) GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900 
 
CYP2B6 Plasmid (NM_000767.4) GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950 
Wild Type (CYP2B6*1)  GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950 
rs2279343 (*4, c.785A>G)  GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950 
rs3211371 (*5, c.1459C>T)  GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950 
 
rs8192709 (*2, c.64C>T)  GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950 
rs12721655 (*8, c.415A>G)  GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950 
 
rs35979566 (*15, c.1172T>A) GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950 
 
CYP2B6 Plasmid (NM_000767.4) CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000 
Wild Type (CYP2B6*1)  CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000 
rs2279343 (*4, c.785A>G)  CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000 
rs3211371 (*5, c.1459C>T)  CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000 
 
rs8192709 (*2, c.64C>T)  CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000 
rs12721655 (*8, c.415A>G)  CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000 
 
rs35979566 (*15, c.1172T>A) CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000 
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CYP2B6 Plasmid (NM_000767.4) CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050 
Wild Type (CYP2B6*1)  CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050 
rs2279343 (*4, c.785A>G)  CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050 
rs3211371 (*5, c.1459C>T)  CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050 
 
rs8192709 (*2, c.64C>T)  CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050 
rs12721655 (*8, c.415A>G)  CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050 
 
rs35979566 (*15, c.1172T>A) CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050 
 
CYP2B6 Plasmid (NM_000767.4) GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100 
Wild Type (CYP2B6*1)  GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100 
rs2279343 (*4, c.785A>G)  GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100 
rs3211371 (*5, c.1459C>T)  GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100 
 
rs8192709 (*2, c.64C>T)  GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100 
rs12721655 (*8, c.415A>G)  GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100 
 
rs35979566 (*15, c.1172T>A) GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100 
 
CYP2B6 Plasmid (NM_000767.4) GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150 
Wild Type (CYP2B6*1)  GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150 
rs2279343 (*4, c.785A>G)  GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150 
rs3211371 (*5, c.1459C>T)  GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150 
 
rs8192709 (*2, c.64C>T)  GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150 
rs12721655 (*8, c.415A>G)  GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150 
 
rs35979566 (*15, c.1172T>A) GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150 
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CYP2B6 Plasmid (NM_000767.4) AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200 
Wild Type (CYP2B6*1)  AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200 
rs2279343 (*4, c.785A>G)  AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200 
rs3211371 (*5, c.1459C>T)  AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200 
 
rs8192709 (*2, c.64C>T)  AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200 
rs12721655 (*8, c.415A>G)  AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200 
 
rs35979566 (*15, c.1172T>A) AGGACACAGA AGTATTTCTC AACCTGAGCA CTGCTCTCCA TGACCCACAC 1200 
 
CYP2B6 Plasmid (NM_000767.4) TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250 
Wild Type (CYP2B6*1)  TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250 
rs2279343 (*4, c.785A>G)  TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250 
rs3211371 (*5, c.1459C>T)  TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250 
 
rs8192709 (*2, c.64C>T)  TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250 
rs12721655 (*8, c.415A>G)  TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250 
 
rs35979566 (*15, c.1172T>A) TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250 
 
CYP2B6 Plasmid (NM_000767.4) TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300 
Wild Type (CYP2B6*1)  TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300 
rs2279343 (*4, c.785A>G)  TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300 
rs3211371 (*5, c.1459C>T)  TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300 
 
rs8192709 (*2, c.64C>T)  TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300 
rs12721655 (*8, c.415A>G)  TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300 
 
rs35979566 (*15, c.1172T>A) TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300 
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CYP2B6 Plasmid (NM_000767.4) GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350 
Wild Type (CYP2B6*1)  GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350 
rs2279343 (*4, c.785A>G)  GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350 
rs3211371 (*5, c.1459C>T)  GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350 
 
rs8192709 (*2, c.64C>T)  GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350 
rs12721655 (*8, c.415A>G)  GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350 
 
rs35979566 (*15, c.1172T>A) GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350 
 
CYP2B6 Plasmid (NM_000767.4) ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400 
Wild Type (CYP2B6*1)  ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400 
rs2279343 (*4, c.785A>G)  ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400 
rs3211371 (*5, c.1459C>T)  ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400 
 
rs8192709 (*2, c.64C>T)  ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400 
rs12721655 (*8, c.415A>G)  ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400 
 
rs35979566 (*15, c.1172T>A) ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400 
 
CYP2B6 Plasmid (NM_000767.4) CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450 
Wild Type (CYP2B6*1)  CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450  
rs2279343 (*4, c.785A>G)  CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450 
rs3211371 (*5, c.1459C>T)  CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450 
 
rs8192709 (*2, c.64C>T)  CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450 
rs12721655 (*8, c.415A>G)  CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450 
 
rs35979566 (*15, c.1172T>A) CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450 
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CYP2B6 Plasmid (NM_000767.4) ACCAGATCCG CTTCCTGCCC CGCTAG 1476 
Wild Type (CYP2B6*1)  ACCAGATCCG CTTCCTGCCC CGCTAG 1476 
rs2279343 (*4, c.785A>G)  ACCAGATCCG CTTCCTGCCC CGCTAG 1476 
rs3211371 (*5, c.1459C>T)  ACCAGATCTG CTTCCTGCCC CGCTAG 1476 
 
rs8192709 (*2, c.64C>T)  ACCAGATCCG CTTCCTGCCC CGCTAG 1476 
rs12721655 (*8, c.415A>G)  ACCAGATCCG CTTCCTGCCC CGCTAG 1476
 
rs35979566 (*15, c.1172T>A) ACCAGATCCG CTTCCTGCCC CGCTAG 1476 
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APPENDIX C: LIST OF ABBREVIATIONS 
AAS… amino acid substitution 
ADH… alcohol dehydrogenase 
AGP… α1-acid glycoprotein 
ANOVA… analysis of variance 
CDC… Centers for Disease Control and Prevention 
CYP… cytochrome P450 
DEA… Drug Enforcement Agency 
del… deletion 
DNA… deoxyribonucleic acid 
EDDP… 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine 
EM… extensive metabolizer 
EMDP… 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline 
FDA… Food and Drug Administration 
hERG… human ether-a-go-go related gene 
HWE… Hardy-Weinberg equilibrium 
IM… intermediate metabolizer 
KY… Kentucky 
LD… linkage disequilibrium 
MAF… minor allele frequency 
MMT… methadone maintenance treatment 
MOR… µ-opioid receptor 
MTD… methadone 
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NADPH… nicotinamide adenine dinucleotide phosphate 
NCBI… National Center for Biotechnology Information 
OCME… Offices of the Chief Medical Examiner 
p-HO… para-hydroxy 
PolyPhen… polymorphism phenotyping 
PM… poor metabolizer 
RT-PCR… real-time polymerase chain reaction 
SEM… standard error of the mean 
SIFT… scale-invariant feature transform 
SNP… single nucleotide polymorphism 
SRS… substrate recognition site 
UM… ultra-rapid metabolizer 
UTR… untranslated region 
VEP… variant effect predictor 
WV… West Virginia 
  
103 
APPENDIX D: CURRICULUM VITAE 
TAHA AHMAD, PHD 
 
Phone: (201) 705-7815 
Taha.Ahmad.NJ@gmail.com 
1443 15th Street 
Huntington, WV 25701 
 
EDUCATION 
 
PhD Marshall University, Biomedical Sciences  May 2019 
Emphases: Pharmacology, Physiology and Toxicology 
Dissertation: “Role of Cytochrome P450 2B6 Polymorphisms in Unexpected Methadone 
Death” 
Committee: Dr. Gary O. Rankin, Dr. Monica A. Valentovic, Dr. Donald A. Primerano, 
Dr. Travis B. Salisbury, Dr. Richard D. Egleton 
 
MSFS Marshall University, Forensic Science  May 2009 
 Emphases: DNA Analysis, Crime Scene Investigation, and Computer Forensics 
 
BS New Jersey City University, Biology and Chemistry May 2005 
 Minored in Mathematics 
 
LABORATORY SKILLS 
 
Experimental Techniques  
o Gel electrophoresis, PCR, Light Microscope, Spectrophotometer, HPLC/UV-Vis, 
UPLC/MS/MS 
o Extract genomic DNA from blood stain cards via QIAamp DNA Micro DNA Kit 
o Quantitate extracted DNA using NanoDrop 1000 
o Genotype CYP2B6 and CYP2C19 SNPs using TaqMan® SNP Genotyping Assay on the 
ABI 7000 Sequence Detection and StepOnePlus instrument and software 
o Determine relationship and correlation of SNPs in CYP2B6 and CYP2C19 genes to 
decreased metabolism of methadone leading to fatal concentrations 
o Perform mutations using a QuikChange II Site-Directed Mutagenesis Kit on CYP2B6 
plasmids, transformation of DH5 and XL-1 Blue cells for amplification of the plasmids, 
purification and sequencing of the plasmids to ensure presence of mutations 
o Perform routine cell culture, cell maintenance and storage, transfections, and selection of 
COS-1 cells 
o Isolate microsomal protein and quantitate protein using Pierce BCA protein assay 
o Measure CYP2B6 activity using P450-GloTM Assay 
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